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Chapter 1
Marine bioactive from brown macroalgae and
the potential role in gastrointestinal health
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1. Introduction
Seaweeds can be classified into Rhodophyta (red), Chlorophyta (green) and Phaeophyta
(brown) according to differences in pigmentation, structural and biochemical properties.
These marine plants have typically been used by the food and cosmetic industries as
sources of thickeners, gelling agents and stabilisers such as alginate, agar and
carrageenan. However, current research has identified the vast potential of seaweed and
seaweed extracts in promoting health. Not only are seaweeds concentrated sources of all
essential nutrients, such as dietary fibres, proteins, vitamins, minerals and
polyunsaturated fatty acids but a variety of extracts isolated from different seaweeds
species have been shown to have rich bioactive potential (Dawczynski et al., 2007;
Černá, 2011). Brown macroalgae in particular has a selection of bioactive compounds
which would not be found in red or green seaweed including fucoidan, a sulphated
polysaccharide mainly found in the cell wall of brown macroalgae, phlorotannin, a
tannin only found in brown macroalgae, and fucoxanthin, a pigment which gives brown
macroalgae its colour. These compounds have been linked to a variety anti-tumour, antiinflammatory, anti-oxidant, anti-coagulant and anti-lipidemic effects which could be
utilised in different food and pharmaceutical applications (Brown et al., 2014; Gupta &
Abu-Ghannam, 2011; Wijesekara et al., 2011; Wijesinghe & Jeon, 2012)
An area which may benefit from these bioactives is the maintenance of gastrointestinal
health. The gastrointestinal tract (GI) functions as a barrier to the entry of pathogens and
is responsible for the absorption of essential nutrient and the regulation of hormones and
is an important contributor to overall health and well-being. Defects in the biological
function of the GI tract can lead to the development of severe gastrointestinal disorders
such as inflammatory bowel disease (IBD). IBD, which includes Crohn’s disease and
ulcerative colitis, is characterized by chronic inflammation in the gastrointestinal tract.
It is widely associated with urbanized societies and with Western style diets, which is
characterized by highly processed and refined foods with a high content of sugar, fat,
salt and protein from red meat. Along with environmental factors, genetic predisposition
to IBD and dysregulation of the gut microbiota has been linked to the pathogenesis of
this disorder (Corridoni et al., 2014). The prevalence of IBD is increasing worldwide
and with long term affliction of IBD associated with increased risk of colorectal cancer,
a major economic burden is placed on the global healthcare system. Thus, alleviatory
and preventative measures are required to lessen this burden. Currently, there are
several methods to treat the symptoms of IBD which include various anti-inflammatory
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drugs, immune system suppressors and, in some severe cases, surgery. However, many
of these methods have a high cost and severe side effects which may be unpleasant for
patients. For this reason, natural compounds from sources such as plants and seaweed
have been examined for anti-inflammatory properties similar to current antiinflammatory drugs, but without any unwanted side effects.
This review will discuss bioactive compounds isolated from seaweed, with emphasis on
those isolated from brown macroalgae, and the potential role they could play in the
maintenance of health, particularly gastrointestinal health.

2. Cultivation of Seaweed
2.1 Global cultivation of seaweed
With increasing global populations, the demand for sustainable sources of raw materials
remains a high priority. Many conventional sources of raw materials are non-renewable
and have become vastly overburdened. Even some renewable sources have been utilised
far beyond their regenerative abilities. Therefore, replacing these over-exploited
resources with sustainable alternatives is crucial. The world’s oceans cover 71% of the
Earth’s surface and host a wide range of biodiverse niches which have remained largely
untapped. Although the ocean remains a significant source of food, increasing numbers
of fish stocks have become over-exploited and are even in danger of becoming extinct,
which has led to an increase in fish farming and aquaculture operations. In 2015, world
aquaculture production reached 106 million tonnes live weight with a total estimated
value of 163 billion US dollars (FAO, 2015). This total production was composed of
farmed aquatic animals, aquatic plants and non-food products (Table 1.1). Aquatic plant
aquaculture has developed in recent years due to the search for innovative sources of
raw materials for the food and pharmaceutical industry. For example seaweed has
generated interest as novel sources of protein and healthy food supplements, as well as
raw materials for other industrial applications.
The use of seaweed by humans has been in practice for a long time. The remains of
seaweed found on a 14,000 year old site in southern Chile have suggested that
inhabitants of the site used seaweed for both human consumption and medicine
(Dillehay et al., 2015). Asia in particular has a long history of seaweed usage outside of
human consumption. Some early examples of medicinal uses of seaweed in Asia
include the use of brown seaweed for goitre and the use of Saccharina strips in difficult
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births to dilate the cervix (The Seaweed Site, 2014). Currently, Asian countries such as
China and Indonesia are the largest producers of seaweed with a combined production
of 25 million tonnes in 2015 (Figure 1.1), (FAO, 2017). While seaweed production in
Asia is well-established due to tradition and taste, the use of seaweed in Europe is not as
recognized and has largely been limited to the extraction of hydrocolloids such as
alginate, carrageenan and agar. However in recent years, the drive towards novel
functional ingredients for food and pharmaceutical products has shifted industry focus
from hydrocolloid extraction to the refinement of high value marine bioactives.
Seaweeds produce a diverse biomass which can be used in a variety of formats i.e.
fresh, dried, extracts or salted for direct consumption or for further processing into food
additives, animal feeds, fertilisers, cosmetic products or functional foods (Rajapakse &
Kim, 2011; Škrovánková, 2011; Anis et al., 2017). As a result, global demand for
seaweed has increased along with increased usage of seaweed beyond traditional
applications. Unlike the lead seaweed producing countries with established seaweed
farming practices, the European seaweed industries rely mainly on the harvesting of
natural resources (Mac Monagail et al., 2017). This could become an issue for future
sustainability as comprehensive information regarding the regenerative properties of
seaweed beds is lacking in many relevant species. The European Marine Biotechnology
(MBT) ERA-NET published a marine biotechnology research and innovation roadmap
identifying biomass production and processing as one of five key areas in the further
development of marine biotechnology (Hurst, 2013). Some long term challenges facing
this area include the sustainable harvesting of marine bio-resources including
macroalgae, as well as the development of in-land and marine aquaculture and the
improved extraction of high-value compounds from marine biomass.
In a bid to promote the growth of marine biotechnology, several European projects have
been funded to tackle several of these challenges. One such strategy is the European
funded At-Sea project, which ended in 2015 and aimed to develop novel technical
textiles in order to demonstrate the economic and technical feasibility of open sea
cultivation of macroalgae (http://www.atsea-project.eu/). Due to the success of this
project, a spin-off company ‘’At Sea Technologies’’, which sells and develops
sustainable turnkey seaweed farms, was co-founded by eight of the partners involved in
the original projects (ATSEA Technologies, 2018). The SWAFAX project, which ended
in 2013, was financed in order to develop extraction techniques for the production of
food grade bioactives from macroalgae species and to evaluate the bioavailability of
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these bioactives using in vitro and short term human trials. The SWAFAX project
produced several food grade polyphenol rich bioactives from the brown seaweed
Ascophyllum nodosum and investigated the bioavailability of these bioactives in humans
along with any additional health benefits (Corona et al., 2016).
Table 1.1: World aquaculture production in 2015
Quantity (live weight)

Value (first sale)

Food fish*

76.6 million tonnes

US$157.9 billion

Aquatic plants**

29.4 million tonnes

US$4.8 billion

Non-food products

41.1 thousand tonnes

US$208.2 million

Total

106 million tonnes

US$163 billion

Figure 1.1: Seaweed production by aquaculture in 2015. Colour scale in metric tonnes (t).
Source: FAO

*

Food fish includes finfish, crustaceans, molluscs and other aquatic animals such as sea urchins and sea
cucumbers, frogs and aquatic turtles, etc. Farmed crocodile and alligators are excluded.
**
Aquatic plants include mostly seaweeds, plus some microalgae.
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2.2 Cultivation of seaweed in Ireland
Many countries with large areas of coastline, including Ireland, could stand to benefit
from increased seaweed cultivation. Predicted revenue from global marine
biotechnology is expected to reach €1 billion by 2020, provided market growth of 6-8%
per annum continues, and this is expected to create 10,000 new jobs (European Marine
Board and Marine Biotechnology ERA- NET (2017)). At present, Ireland’s seaweed
and marine biotechnology sector is estimated to be worth €18 million annually
(Morrissey et al., 2011). A report commissioned by Bord Iascaigh na Mara suggested
that in order for the Irish seaweed sector to reach the expected value of €30 million per
annum by 2020, the sector must capitalise on its wild resources as well as expand its
seaweed aquaculture sites (Walsh & Watson, 2011). There are currently only a few
licensed aquaculture sites in Ireland and much of the country’s seaweed production is
achieved through manual harvesting. The introduction of mechanised harvesting tools in
order to intensify seaweed yield has generated interest due to a decline in young
workers willing to engage in the hard and dirty work involved in seaweed harvesting.
However, several wildlife conservation charities have raised concerns regarding the
environmental impacts mechanical harvesting may have Ireland’s native shores.
Therefore harvesting trials should be conducted in order to investigate its impact on the
regenerative capabilities of seaweed.
With increased interest in aquatic plants as functional ingredients, multiple strategies
have been put in place to promote the development of sustainable aquaculture in
Ireland. The Sea Change project, which took place from 2007-2013, aimed to develop
Ireland’s marine sector into a significant contributor to Irelands’ economy. As part of
this national project, industry scale hatcheries and growing trials were developed for
four species of native seaweeds: Palmaria palmata, Laminaria digitata, Saccharina
latissima and Porphyra sp. (Dring et al., 2013) (Figure 1.2). While Palmaria palmata
and Porphyra sp. proved difficult to cultivate, through the modification of techniques
used in Europe for related kelp species, L. digitata and S. latissima were successfully
cultivated and grown out at sea, indicating the potential for future commercial
cultivation of these seaweed species as a sustainable marine resource. Areas with
invested interest in seaweed cultivation highlighted by this report included functional
foods, cosmetics and pharmaceuticals.
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According to the HARVEST Atlantic project many marine biotechnology companies
surveyed in Ireland were concerned with fish, sea minerals and seaweed, with 38% of
those companies involved in aquaculture and only 12% involved in research and
development (Corcoran et al., 2014). Most of these marine biotechnology companies
are actively involved in innovation in the form of new product development and
marketing strategies, which has led to an increased range of products and improved
quality of products. Currently, there are a range of Irish seaweed-based products
available on the market which range from edible seaweeds, seasonings, snacks, teas,
soaps, cosmetics, fertilisers and animal feeds. Many of these products can be
categorised as high volume but low value products. Brown seaweeds, which are the
most commonly cultivated seaweeds in Ireland, are comprised of a host of bioactive
compounds which could be exploited by the food and pharmaceutical industry.
Improved extraction and formulation of these compounds into value-added functional
ingredients for functional foods, dietary supplements and pharmaceuticals will increase
Ireland’s share in the global marine biotechnology market, as a large quantity of Irish
products from this sector are exported internationally to Europe and even further afield.
Therefore adoption of the “ biorefinery approach’’, i.e. the successive extraction of
valuable components from seaweed biomass, while leaving the remainder unmodified,
in the seaweed industry has been suggested in order to achieve the maximum value
from seaweed production (Balina et al., 2017).

Figure 1.2: Illustration of some native seaweed species of Ireland. From left to right:
Palmaria palmata, Laminaria digitata, Porphyra spp and Saccharina latissima
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3. Seaweed as a preservative in the food industry
The global food market is continually growing and with rising exports to distant
countries the demand for high quality, safe food is increasing. Preservatives are a
fundamental component of meeting these demands. These compounds are used to
maintain quality, extend shelf life and ensure the safety of fresh and processed foods
through the inhibition of microbial growth and by preventing the release of reactive
oxidative species (ROS). To ensure food safety and quality, a range of synthetic antimicrobial agents (weak organic acids, hydrogen peroxide and chelators) and synthetic
anti-oxidant compounds (butylated hydroxytoluene (BHT), butylated hydroxyanisol
(BHA), propyl gallate (PG) and tertbutyl hydroquinone (TBHQ) have been used as
preservatives by the food industry (Brul & Coote, 1999; Shahidi, 2000). However, these
compounds are suspected to be mutagenic and excessive intake has been found to cause
liver damage. As a result, consumer preferences has started to shift from processed,
ready to eat foods, towards additive free food or food with effective preservatives from
natural sources (Tiwari et al., 2009). Terrestrial and marine plants are important sources
for the extraction of natural preservatives which can be used alone or in conjunction
with non-thermal preservation methods. Seaweed bioactives have been marked for use
in nutraceutical and in functional foods, but these compounds have also been found to
have potent anti-oxidant and anti-microbial properties, which indicates their potential as
natural preservatives in the food industry

3.1 Seaweed as an antimicrobial agent
By nature many food products are perishable and subject to contamination by bacteria
and fungi, which can cause undesirable reactions that affect the flavour, odour, textural
and sensory properties of foods. Microbial contamination is a major concern as some
microorganisms can cause foodborne illness. In 2014, for example, 5,251 food-borne
outbreaks, including water-borne outbreaks, were reported in the EU, and bacterial
toxins accounted for 16.1% of these outbreaks (European Food Safety Authority, 2015).
In recent years, due to consumer concerns regarding synthetic additives in food and the
rise of antibiotic resistance in some bacterial strains, numerous efforts have been made
by the food industry to source natural compounds with potent antimicrobial properties.
In general, when compared to red and green seaweeds, brown macroalgae tends to have
greater efficacy in inhibiting the growth of pathogenic bacteria. A study investigated the
anti-bacterial activities of extracts from several native Irish seaweeds, namely,
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Laminaria digitata, Laminaria saccharina, Himanthalia elongate, Palmaria palmata,
Chondrus crispus and Enteromorpha spirulina against four common food spoilage
bacteria Listeria monocytogenes, Salmonella abony, Enterococcus faecalis and
Pseudomonas aeruginosa. While all seaweed extracts, excluding those from C. crispus,
inhibited the growth of the bacteria it was determined that the brown seaweed species,
L. digitata, L. saccharina, H. elongata, had significantly higher antimicrobial activities
than the red and green species which has been linked to their total phenolic content
(Cox, 2010).
Many seaweed extracts have shown potent antimicrobial activity against a number of
Gram negative and Gram positive bacteria. The antibacterial activity of essential oils
from four edible seaweeds - Enteromorpha linza, Undaria pinnatifida, Laminaria
japonica, and Porphyra tenera against three strains of L. monocytogenes, a virulent
bacterium which causes severe foodborne illness was investigated. It was determined
that the essential oil isolated from the green macroalgae E. linza had a greater inhibitory
action as it inhibited the growth of all three strains of Listeria rather than just the two
strains seen in the other essential oils (Patra & Baek, 2016). Another example includes
the extract polyhydroxylated fucophlorethol, from the brown macroalgae Fucus
vesiculosus, which displayed antibacterial activity against both the Gram negative
bacteria Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis and the Grampositive bacteria Staphylococcus aureus and Staphylococcus epidermidis (Sandsdalen et
al., 2003). In contrast Gupta et al (2010), found that the methanol extracts of
Himanthalia elongata, Saccharina latissima and Laminaria digitata had a more
pronounced anti-bacterial effect against Gram negative bacteria (S. albany and P.
aeroginosa) when compared with Gram positive bacteria (L. monocytogenes and E.
faecalis). It was also determined that the application of heat to these extracts caused
degradation of their anti-microbial activities. As anti-microbial properties of these
bioactives are dependent on the extraction method and seaweed species of origin, more
research should be carried out to isolate an appropriate method to create effective antimicrobial extracts.

3.2 Seaweed as an anti-oxidant
Anti-oxidants have a long history of use in the food industry. Increased global
urbanization has generated the need for high-quality products with extended shelf-lives
and improved ability to survive extended transportation. One of the major challenges for
the food industry to reach these goals is the prevention of oxidation. Lipid oxidation
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negatively influences many food characteristics including flavour, nutritional quality,
texture and colour. The presence of reactive oxygen species (ROS) such as superoxide
anions and the hydroxyl radical are common causes of food decay and rancidity. Antioxidants such as BHT (butylated hydroxytoluene), BHA (butylated hydroxyanisol) and
TBHQ (tertbutyl hydroquinone) are used to prevent oxidation in foods with both high
lipid contents, such as vegetable oils, animal fats and processed meats, and in foods
with low lipid contents, such as cereal and grains. Currently there is interest in finding
natural anti-oxidants which are effective enough to substitute commercial synthetic antioxidants due to consumer interest in minimally processed, additive free food products.
The use of seaweeds as a natural preservative is of interest due to their rich antioxidant
capabilities. A strong correlation between phenolic content and antioxidant activity of
seaweed extracts has been elucidated by several studies. A study of the antioxidant
potential of eight Malaysian seaweed species found that extracts from two green
seaweeds (Caulerpa lentillifera and C. racemose) and brown seaweed (S. polycystum)
had a greater radical scavenging ability and antioxidant reducing power than other
seaweed species assayed. These antioxidant capabilities were correlated with the high
level of phenol content in each species (Matanjun et al., 2008). Additional metabolites
in brown seaweed have been identified to have potent antioxidant activities. The marine
carotenoid fucoxanthin and its metabolite fucoxanthinol were found to have potent
radical scavenging activities, with scavenging activity of fucoxanthin 13.5 times higher
than α-tocopherol, an anti-oxidant which is absorbed and accumulated in humans
(Sachindra et al., 2007).
However, when investigating extracts from seaweed for antioxidant properties, the
extraction method should be taken into consideration. Both processing and extraction
methods have an effect on the total phenolic content and antioxidant ability of the
seaweed species. A study investigated the effect of processing and extraction methods
on antioxidant activities of extracts from the red macroalgae Porphyra tenera. In the
study, the laver was dried, roasted or seasoned and extracted by means of hot water
extraction or ethanol extraction. It was determined that antioxidant activity of dried,
roasted and seasoned laver increased in a concentration - dependent manner while
ethanol extracts had higher free radical scavenging abilities when compared to water
extracts (Hwang & Thi, 2014). A similar study investigated the effect of hydrothermal
processing on antioxidant and free radical capability of edible Irish brown seaweed,
Laminaria saccharina, Laminaria digitata and Himanthalia elongata. When compared
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with raw samples of the same seaweed species it was determined that both total
phenolic content and free radical scavenging abilities were increased after hydrothermal
processing (Rajauria et al., 2010).

4. Environmental effects on brown macroalgae growth & composition
Brown macroalgae, also known as Phaeophyta, is one of the largest and most complex
classes of seaweed. Its characteristic brown colour is due to the presence of fucoxanthin,
a pigment which is not found in any other class of seaweed. Like other macroalgae,
brown macroalgae has a broad distribution, from tropical to temperate climates. Brown
macroalgae species such as Laminaria hyperborean and Ascophyllum nodosum are
often used in industry as sources of alginates, derivatives of alginic acids, which are
commonly used as stabilizers, emulsifiers and binding agents. Recent research has
identified several bioactive compounds in brown macroalgae which could be used in a
host of applications in the food and pharmaceutical industry. However, a barrier to
consistent functional ingredients is the variable composition of seaweeds throughout the
year. Because of the growth environment, seaweeds are often exposed to varying
degrees of environmental conditions. Seaweed composition, yield and biomass often
varies according to harvesting season, temperature, salinity and light intensity which
would prove a problem for consistent extraction of novel bioactives. Therefore in-depth
seasonal studies are required to not only evaluate the effect of this variation on
composition of seaweed extracts but to determine the best harvesting strategy for each
species.

4.1 Seasonal change
Harvesting season is an important concept in the seaweed industry. During seaweed
aquaculture, sporocytes are typically seeded in ropes or nets and then fixed at certain
depths in the sea. Harvesters continually examine these ropes to determine optimum
biomass for harvesting. Similar to terrestrial plants, seaweeds have seasons in which
peak growth is achieved. This season can often differ, depending on seaweed species
and method of growth. For example, Sargassum polycystum, a brown macroalgae
common to Indian waters, was harvested from the wild and found to achieve maximum
growth during the winter months (Srinivasa Rao & Umamaheswara Rao, 2002). In
contrast, the cultivated kelp species Saccharina latissima demonstrated optimal growth
in autumn and spring (Handå et al., 2013).
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The variability of seaweed composition and extract bioactivity is also largely influenced
by harvesting season. A study investigating the nutritional composition and antiproliferative activity of Sargassum oligocystum samples from four different seasons in
Thailand found that, in general, nutritional content was high during the hot dry and
early monsoon season (February and May). Ethanolic and lipophilic extracts from the
monsoon season (August) were shown to have a more effective anti-proliferative
activity against a lung cancer cell line. Similar studies have found seasonal variations in
composition in other species of seaweed (Praiboon et al., 2017). Marinho et al., (2015),
found that total lipid content of Saccharina latissima increased in winter and decreased
in summer, a pattern which has been observed for other brown macroalgae species as
well as in some red and green macroalgae (Nelson et al., 2002). Seasonal variation
presents an obstacle to consistent isolation of bioactives such as fucoidan, due to their
varying concentrations in seaweed throughout the year. A study carried out on three
species of brown macroalgae - Saccharina japonica, Sargassum pallidum, and
Stephanocystis crassipes demonstrated maximum fucoidan content in different time
periods for each species which has been linked to the development of reproductive
organs (Skriptsova, 2016). Much of the variation in seaweed composition may be
caused by changes in environmental temperature, light intensity, salinity and presence
of essential nutrients as caused by the changing of the seasons.

4.2 Water Temperature
Another possible contributing factor to the variability of seaweed biomass is the
environmental temperature. Due to genetic adaption over millions of years, each
seaweed species has an optimum temperature range which usually correlates with local
temperature conditions. For example, Antarctic seaweed would have a narrow
temperature range due to little variation in local temperature, while temperate seaweed
species have one of the broadest temperature ranges due to larger seasonal changes in
temperature (Buchholz et al., 2012). Within this temperature range growth is at its peak,
with growth rapidly declining above this range.
Seaweeds have the ability to acclimatise growth and photosynthesis in response to
daily/seasonal changes in ambient temperature. This phenotypic acclimatisation usually
allows maximum growth at a broader temperature range and can vary between species.
A recent study carried out on five common seaweed species from Atlantic Canada,
including Ascophyllum nodosum, Fucus vesiculosus, Chondrus crispus, Laminaria
digitata and Codium fragile ssp. Tomentosoides, investigated the effect of an increase in
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environmental temperature on the growth and survival of these species. It was
determined that the kelp species, L. digitata, followed by the rockweed species,
Ascophyllum nodosum, F. vesiculosus, had the worst growth and survival in higher
temperatures, while the red and green seaweed species, C. crispus and Codium fragile
ssp. Tomentosoides respectively, had high survival rates in all temperature conditions
(Wilson et al., 2015). The low survival rate of kelp species beyond 20°C has been
established in similar studies. A study carried out on the kelp species S.latissima
collected from Norway, determined that this species can optimise photosynthesis at
temperatures within the range of 10°C to 15°C (Andersen et al., 2013). However,
beyond this range, poor performance and higher mortality rates were seen. Poor
performance at high temperatures could be due to the degradation of essential proteins
and enzymes in seaweeds.
Therefore, rising sea temperatures could present as a possible concern to the marine
industry. A study carried out in Japan attempted to predict the continued effect of rising
sea temperatures on the distribution of Ecklonia cava, a brown macroalgae which has
been in decline in recent years due to global warming and heavy grazing by marine
organisms (Takao et al., 2015). The study predicted the decline of E .cava populations
at both high and low emission scenarios either through increased temperature stress or
through increased grazing by marine herbivores. Rising sea temperatures may affect the
natural distribution and performance of many seaweed species particularly brown
macroalgae.

4.3 Light Intensity
Temperature effects on the growth of seaweeds are often linked with light intensity.
Light is an essential component of any plant growth, due to its role in photosynthesis.
Depending on the habitat of the seaweed species, growth could be dependent on high or
low light requirements which can often correspond with environmental temperatures.
Artic brown macroalgae species (i.e. S. latissima, L. digitata, A. esculenta) have adapted
to grow and photosynthesize under very low temperatures and under low light
intensities. However, exposure of the micro-stages of these Artic species to high levels
of UV radiation along with high temperatures has been linked with reproduction and
sporocyte formation (Müller et al., 2008).
Brown macroalgae have effective photo-protective responses to deal with high light
stress. The xanthophyll-cycle, also known as the violaxanthin cycle, is an important
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photo-protection mechanism found in most plants. During this cycle a reversible
conversion reaction of the carotenoid violaxanthin by the intermediate antheraxanthin
into zeaxanthin takes place. This allows photosynthetic light harvesting complexes to
switch from light harvesting under low light conditions to light dissipating under high
light conditions (Figure 1.3) (Jahns et al., 2009; Goss & Jakob, 2010). The efficiency
of these protective mechanisms often depends on the habitat of the species. A study
compared the light response of Laminaria abyssalis, which grows in deep waters and
low light, and L. digitata, which grows in shallower waters and exposed to higher light
intensities. It was determined that L. abyssalis had lower tolerance of high irradiation
which may be due to its reduced xanthophyll-cycle pool size (Rodrigues et al., 2002).
Brown macroalgae also produces several compounds of interest such as fucoxanthin and
phlorotannins, which have been linked to protective responses to light induced oxidative
stress (Cruces et al., 2013). However, the photo-protective activities of these
compounds are often impaired by exposure to temperatures beyond normal growth
range. Therefore, in a future scenario of higher sea temperatures and increased exposure
to UV radiation, the growth and distribution of several key brown macroalgae species
may be significantly altered.
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Figure 1.3: Photo-protection by dissipation of excess light energy aided by
xanthophyll cycle carotenoids. The xanthophyll violaxanthin is converted to
zeaxanthin (via the intermediate antheraxanthin) whenever chloroplasts absorb
excess light. Zeaxanthin acts as a key facilitator of the dissipation of excess 1Chl*.
Conversely, when light is not excessive, zeaxanthin is disengaged from energy
dissipation and converted back to violaxanthin, thereby returning to an efficient
utilization of light energy in photosynthesis (Nature.com, 2018)
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4.4 Salinity
The growth, survival and distribution of marine macroalgae are often determined by
their ability to tolerate environmental stresses. One such environmental stress is a
change in ambient salinity. Salinity is a technical term used to describe the
concentration of dissolved salts in a body of water. On average, the salinity of the open
ocean is approximately 35 parts per thousand (ppt). Salinity gradually decreases as you
move from tropic to polar seas due to lower levels of evaporation and increased
freshwater sources. As with temperature and light intensity, salinity tolerance of marine
macroalgae is often dependent on habitat. Many seaweed species grow in fixed
positions, either attached to rocks or other hard substrata, and as such, they are exposed
to fluctuations in salinity levels during low tides. As a result macroalgae have
developed effective adaptive and tolerance strategies in response to variations in
ambient salinity including extensive ROS detoxification, accumulation of solutes which
maintains cellular membrane integrity and adjust cellular osmotic content (i.e. amino
acids such as proline, carbohydrates such as sucrose and polyols and quaternary
ammonium compounds such as glycine betaine and proline betaine) and altered ion
homeostasis (Kumar et al., 2014).
Due to climate change, ambient salinity may change in some regions, leading to shifts
in macroalgae distribution. In South American regions, increased precipitation has led
to increased levels of freshwater, thereby causing a decline in salinity levels. Growth of
Sargassum stenophyllum, brown seaweed common to this region, was found to be
negatively affected by changes in salinity levels, indicating potential population shifts in
the marine community (Scherner et al., 2013). Prolonged exposure to reduced ambient
salinity has been linked to inhibition of photosynthesis and reduced growth (Connan &
Stengel, 2011). Ambient salinity is also a contributing factor towards industrial
utilization of marine bioactives as habitat often influences the yield and composition of
seaweed. For example, fucose-containing sulphated polysaccharides from brown algae
have been linked with distinct health-promoting properties; prompting industry focus on
availability and quality of these bioactives. Ehrig & Alban., (2015) found that
S.latissima harvested from the North Atlantic in autumn had a higher yield of fucosecontaining sulphated polysaccharides than S.latissima harvested from the Baltic Sea
which has a much lower salinity. In conclusion, when harvesting seaweed for the
targeted isolation of specific bioactives, habitat as well as harvesting season should be
considered as influencing factors on yield and bioactivity of the compounds
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4.5 Biofouling
Like other eukaryotic organisms, marine macroalgae host a complex and diverse
community of microorganisms with essential roles in health and defence (Singh &
Reddy, 2014). Epiphytic bacterial communities in particular have essential roles in
normal growth and morphology of algae species. A study carried out on the green
macroalgae Ulva fasciata determined that when the macroalgae were cultured in an
axenic environment, abnormal morphology developed (Singh et al, 2011). The addition
of bacteria isolates from different Ulva species induced normal morphology, indicating
a symbiotic relationship between the development of the macroalgae species and its
bacterial community.
However, not all marine microorganisms are beneficial towards seaweed growth.
Biofouling, which is a term used to describe the accumulation of microorganisms,
plants or animals on wetted surfaces, is a major barrier which can prevent year round
cultivation of macroalgae. Encrusting bryozoan species in particular are a challenge in
the cultivation of kelp species such as Saccharina latissima. These microorganisms
develop colonies on the surface of the kelp, weakening its structure and making its
blades more prone to breakages. Prolonged exposure to the invasive bryozoan
Membranipora membranacea decreases tissue strength in kelp species, thereby
reducing the marine plants’ ability to withstand waves (Krumhansl et al., 2011). A
study determined that the settlement period of two encrusting bryozoan species
M.membranacea and Electra pilosa on kelp occurred around mid-June, with rapid
colonization observed in late June and July (Figure 1.4), (Førde et al., 2016). In order to
avoid seasonal biofouling and harvest the optimum seaweed biomass, seaweed
producers are often restricted in their harvesting time.
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Figure 1.4: Seasonal lifecycle of bryozoan species. During winter
months bryozoan survive in resting stages (statoblasts).
Proliferation occurs in spring and summer months. During summer
months bryozoan larvae are released and colonies grow rapidly and
disperse by fragmentation and re-attachment of branches.
SB=statoblasts, L= larvae, F=fragmentation. (Okamura et al, 2015)

Figure 1.5: Close up view of Membranipora membranacea
colony
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5. Nutritional benefits of brown seaweed
Many countries in which seaweed is a staple in the diet have higher life expectancies
and lower rates of morbidity and disease. The island of Okinawa has one of the highest
life expectancy rankings in Japan, along with lower rates of age associated diseases. A
strong correlation has been identified between these lower disease rates and the typical
Okinawa diet which is low calorie, nutrient dense and reduced in meat, saturated fats,
sugar and dairy products. A study carried out on Okinawan immigrants living in Brazil
identified higher obesity rates and higher hypertension than their counterparts living on
the island, which may be linked to changes in lifestyle and therefore dietary habits
(Moriguch et al., 2004). More than a dozen varieties of seaweed, including kombu,
wakame and nori, are commonly used in the Okinawa diet which may contribute
towards these health effects. Nutritional analyses of different seaweed species have
identified the marine algae as low calorie sources of all essential nutrients, many of
which have been marked with bioactive potential for use in the food, feed and cosmetic
industry.

5.1 Carbohydrates & Dietary Fibre
Seaweeds are a rich source of carbohydrates and dietary fibre. The typical
polysaccharides found in brown seaweeds, which includes cellulose, laminarin,
mannitol and alginate, cannot be digested by human digestive enzymes and therefore
makes seaweed an important source of dietary fibre. The benefits of fibre consumption
have been well documented in scientific literature, particularly in digestive health.
Dietary fibre has been linked with the prevention of Type II diabetes, obesity,
inflammation and certain types of cancers (Kaczmarczyk et al., 2012). Approximate
total dietary fibre content in edible seaweed has been estimated to be within the range of
36-62% dry weight, of which a large quantity consists of soluble fibre (Dawczynski et
al., 2007; Gómez-Ordóñez et al., 2010).
Fibre can be sub-classified into soluble and insoluble fibres depending on their degree
of solubility. Soluble fibres are easily fermentable fibres, which form a gel when
dissolved in water, while insoluble fibres provide bulking action and tend to be only
fermented by anaerobic bacteria in the colon. Consumption of soluble fibre has been
shown to reduce cholesterol levels, lower blood pressure, improve digestive disorders
and improve weight management through delayed gastric emptying (Anderson et al.,
2009). The immunomodulatory effects of soluble fibres and resistant starches have also
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been investigated in animal models of inflammation, demonstrating the potential of
soluble fibre in IBD therapies (Bassaganya-Riera et al., 2011). Much of these health
benefits can be attributed due to the role of soluble fibre in short chain fatty acids
(SCFA) production. Both soluble and insoluble fibres are fermented by the microbiota
in the gut to produce quantities of SCFA which have roles in the reduction of
inflammation, improved barrier function of the gut and regulation of gut hormones
(Peng et al., 2007; Tedelind et al., 2007; Psichas et al., 2015). As seaweed has high
quantities of fibre, particularly soluble fibre, their potential for incorporation into
functional products aimed at the improvement of health has generated increasing
amounts of interest. For example Ulva ohoni, a green seaweed rich in soluble fibre and
magnesium, has been found to reduce symptoms of metabolic syndrome in rat models
more effectively when compared with Derbesia tenuissima, which had high levels of
insoluble fibre (Kumar et al., 2015).
5.1.1 Seaweed polysaccharides as prebiotics

Seaweed carbohydrates have also been identified as emerging sources of prebiotics. The
gastrointestinal tract hosts a complex microbial ecosystem which supports normal
function of the gut. Imbalances in this microbial community has been observed in many
chronic diseases related to the gastrointestinal tract such as obesity, IBD, Type II
diabetes and enteric infections, suggesting a correlation between the gut microbiota and
health (Boulangé et al., 2016; Matsuoka & Kanai, 2015; Larsen et al., 2010; Singh et
al., 2015). Probiotics are often recommended as a means of correcting imbalances in the
gut microbiota. However, the introduction of these healthy microorganisms in order to
improve health is not always effective, as they must firstly survive the acidic
environment of the stomach and secondly compete with the natural flora of the large
intestine in order to exert favourable effects. Therefore the use of prebiotics, indigestible
food ingredients which stimulates the growth of one or a limited number of the natural
flora in the intestine thereby conferring beneficial effects, should be considered.
Based on the three main criteria regarding prebiotics (non-digestibility, fermentative
ability and selectivity), in vitro studies have identified several seaweed extracts as being
rich in prebiotic potential. For example laminarin, the seaweed polysaccharide, has been
shown to be resistant to hydrolysis by human digestive enzymes and was found to act as
a modulator of intestinal metabolism through increased production of short chain fatty
acids (SCFAs), lowering the intestinal pH (indicative of bacterial growth) and altering
the mucus composition of animal models (Devillé et al., 2004; Devillé et al., 2007).
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However, these studies suggest that while laminarin has a beneficial effect on the gut,
the polysaccharide is not selectively fermented. When screening potential prebiotics, it
is more desirable that the compound is fermented by the beneficial intestinal flora, such
as Lactobacillus and Bifidobacterium, and not by potentially pathogenic strains in the
gut (Figure 1.6).
While the prebiotic selectivity of laminarin has not been demonstrated, other seaweed
extracts have been found to selectively promote growth of beneficial bacteria and inhibit
the growth of pathogenic strains. Kong et al., (2016) found that sulphated
polysaccharides from L. japonica and E. prolifera fermented by human faecal cultures
significantly increased SCFA production and promoted the growth of Lactobacillus and
Bifidobacterium. These prebiotic effects were reported to be linked to molecular weight
of the sulphated polysaccharides. Similar studies have found that differences in physiochemical properties of seaweed extracts have an influence on prebiotic activities which
may be because some compounds are more susceptible to fermentation (Rodrigues et
al., 2016; Ramnani et al., 2012). In vivo studies have found that supplementation with
seaweed extracts improves growth performance of pig and reduces E. coli and
Enterobacteriaceae populations in the gut (Leonard et al., 2011; Smith et al., 2011). It
is clear that seaweed extracts are emerging sources of novel prebiotics both for human
health and for use in the agricultural sector to improve growth performance of cattle.
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Figure 1.6: Distribution of the dominant, sub-dominant and minor
components of human faecal microflora. *Major dominant phyla
are denoted. Other components are at the family or genus level.
(O’Sullivan et al, 2010)
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5.2 Proteins
Global food requirements are constantly expanding along with global populations.
However, some essential nutrient sources such as proteins have been predicted to be in
short supply in the future, prompting industry driven research into novel and sustainable
sources of proteins. Seaweed has been considered a viable source of protein. A study
carried out on the brown macroalgae Himanthalia elongata, Bifurcaria bifurcate and
Laminaria saccharina (also known as Saccharina latissima) determined that the protein
content was within the range of 10.95-25.7% dry weight, with Laminaria saccharina
containing the highest protein fraction (Gómez-Ordóñez et al., 2010). Protein content
usually varies according to species and seasonal variation but is typically within the
range of 3-47% dry weight, with red and green seaweed having higher protein content
than brown seaweed (Fleurence et al., 1999).
Amino acid analysis of proteins isolated from 34 edible seaweeds was determined to be
rich in all essential amino acids (EAA), particularly threonine, valine, leucine, lysine,
glycine and alanine. In contrast to red macroalgae, levels of individual amino acids were
found to vary between brown macroalgae species (Dawczynski et al., 2007). This
pattern seemed to be displayed in other studies. A study on the nutritional composition
of three brown macroalgae, Padina pavonica, Dictyota dichotoma and Colpomenia
sinuosa, determined that total EAA levels in P. pavonica were suitable to meet the
requirements set out by the WHO/FAO, whereas total EAA content in D. dichotoma
and C. sinuosa were insufficient (Tabarsa et al., 2012). As the EAA profile is a common
tool used to assess novel proteins, the total amino acid profile of the seaweed protein
should be examined in order to determine its acceptability in human and animal
nutrition.
However, digestibility of these proteins should be considered as a barrier towards the
utilization of seaweed as a novel protein source. There are many exogenous and
endogenous factors which may negatively affect digestibility of seaweed protein
including species, seasonal variation and presences of various anti-nutritional
compounds such as polysaccharides and phenolic compounds (Fleurence et al., 1999).
Polysaccharides contained in the cell walls of seaweed, particularly brown seaweed,
form stable complexes with proteins, which negatively influences protein digestibility.
These polysaccharides often behave like soluble fibres which have been shown to
reduce pepsin activity and thereby negatively influence protein digestibility (Horie et
al., 1995). As a result, extraction methods such as enzyme hydrolysis, mechanical
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grinding, ultra-sound assisted extraction and pulse electric field extraction have been
utilised in order to improve algal protein bioavailability (Bleakley & Hayes, 2017).

5.3 Polyunsaturated Fatty Acids (PUFAs)
In general, seaweed has low total lipid content in comparison to other essential
nutrients. Total lipid content within edible macroalgae is usually around 2% dry weight,
with very little variation between red and brown species (Dawczynski et al. 2007)
(Dawczynski et al., 2007). A high proportion of that lipid content is contributed by
health promoting long chain polyunsaturated fatty acids (PUFAs) such as
eicosapentaenoic acid (EPA) and arachidonic acid. PUFAs are essential nutrients which
cannot be synthesized in the body and therefore must be included in the diet. However,
intake of PUFA’s are generally insufficient to meet the recommended requirements set
out by the FAO/WHO. A recent European survey on dietary fatty acid consumption
determined that of the countries surveyed, only half met the recommended PUFA intake
range of 6-11% total energy, with fats, oils and cereal products being the main
contributing dietary factors (Eilander et al. 2015) (Eilander et al., 2015). Therefore
novel, renewable sources of these bioactive are required in order to meet these
recommendations in all countries.
PUFAs contain two classes of compounds: omega-3 fatty acids (n-3) such as α-linolenic
acid (C18:3, n-3) and omega-6 fatty acids (n-6) such as linoleic acid (C18:2, n-6). These
PUFAs act as precursors to long chain PUFAs which have important biological
functions in the body. For example, the n-3 fatty acids EPA and DHA have been linked
with proper foetal development, improved risk of cardiovascular disease and improved
cognitive function in those suffering from mild Alzheimer’s disease (Swanson et al.,
2012). Higher levels of PUFAs have also been linked to improved gastrointestinal
health through the reduction of obesity, improved insulin resistance and potent antiinflammatory actions (Ruzickova et al., 2004; Albert et al., 2014; Monk et al., 2012).
Seaweed lipids are ideal sources of essential fatty acids as in most cases the n-6: n-3
ratio is typically below 1 (Dawczynski et al., 2007; van Ginneken et al., 2011). The
WHO have set out a recommended n-6/n-3 ratio of less than 10 in order to prevent the
development of cardiovascular, inflammatory and neuronal disorders. However,
Western diets are typically deficient in omega-3 fatty acids and therefore have an
estimated n-6/n-3 ratio of approximately 15/1 to 16.7/1. The inclusion of low n-6/n-3
ratio seaweed products in Western diets could help alleviate many health concerns
through dietary intervention.
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5.4 Vitamins
Due to their habitat, seaweeds are often exposed to sunlight for long periods of time
which stimulates the production of antioxidant compounds such as vitamins. As with
other nutrients, vitamin levels often vary according to seaweed species, season of the
year, salinity, sea temperature and light intensity. Seaweeds contain both water-soluble
and lipid-soluble vitamins including, vitamin C, vitamin B, provitamin A and vitamin E,
in levels usually sufficient to meet most recommended daily intakes for vitamins (Table
1.4). For example several edible seaweed such as Macrocystis pyrifera, Ulva lactuca
and Durvillaea antarctica have been found to contain high levels of tocopherols when
compared with traditional sources of tocols such as plant oils (Škrovánková, 2011; Ortiz
et al., 2006)
Some seaweed species have been identified as potential sources of vitamin B12, which
is not usually found in land plants. Vitamin B12 is a water soluble vitamin which works
in conjunction with folate in the synthesis of DNA and red blood cells and is essential
for the normal function of the brain and nervous system. Previous research has
identified some algal species, as well as algal based food products, as sources of vitamin
B12. However, the bioavailability of B12 from these sources varies. A diet of dried nori
leaves were found to improve hepatic B12 levels in B12 deficient rats, which indicates
its bioavailability in mammals (Takenaka et al., 2001). In contrast, spirulina tablets
were found to be unsuitable as a source of B12 for mammals as pseudovitamin B12, a
biologically inactive corrinoid, is predominant in spirulina tablets (Watanabe et al.,
1999; Watanabe et al., 2002)

5.5 Minerals
Seaweeds are often considered concentrated sources of minerals due to their exposure to
a wide variety of earth elements in their habitat, and their ability to concentrate these
rare elements. As a result, these marine plants typically have a higher content of
calcium, sodium, magnesium and potassium, along with trace minerals such as iodine,
zinc and iron, when compared with terrestrial plants. For example, Porphyra spp and
Ulva lactuca have a higher content of bioavailable iron when compared with spinach
(Flores et al., 2015). This abundance of minerals has the potential to be utilized in the
production of novel functional foods for health as the mineral content of seaweeds are
usually sufficient to meet daily nutrient requirements (Table 1.4). One such example of
an algal functional food is seaweed supplemented chocolate. This product was
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developed as a means of improving iron intake in anaemic adolescent girls as
haemoglobin levels, total iron binding capacity and serum iron levels were improved
after dietary supplementation (Thahira Banu & Uma Mageswari, 2015). Another
application of algae in the food and health industry is the development of algal mineral
supplements. Aquamin F is a calcium and magnesium rich, multi-mineral alagal
supplement, which has been linked with the treatment of osteoporosis through improved
bone formation and reduced inflammation (O’Gorman, Tierney, et al., 2012;
O’Gorman, O’Carroll, et al., 2012)
However, heavy metal pollution is a factor which can hinder the safety of seaweed as a
food product. Inorganic arsenic, lead, mercury, copper and cadmium in particular are a
concern, as chronic exposure to these heavy metals can lead to serious health risks. In
Europe, there is little to no legislation focused solely on seaweed and seaweed
containing products. Seaweed in general is considered as a novel food in Europe;
however several edible macroalgae and microalgae species have been marked as not
novel i.e. consumed to a substantial degree in the EU before May 1997 (Table 1.2). As
such, these seaweeds are often classified under general regulations for food products
(Table 1.3). However, legislation waivers for cadmium and lead were awarded as higher
levels of these heavy metals occurs innately in macroalgae. A study was carried out to
compare the heavy metal content in edible seaweed products to heavy metal legislation
used in Spain. One hundred and twelve samples were assayed, including packaged
seaweed products, canned seaweeds, seaweed tablets and extracts and food containing
seaweed. A failure to comply with heavy metal legislation was observed in all assayed
products, indicating a need for seaweed specific regulation (Almela et al., 2006). France
was one of the first countries to assign specific regulations to seaweed based food
products and has subsequently set out maximum heavy metal levels in seaweed destined
for consumption (Table 1.4). Therefore, in order to ensure safety of consumers, clear
and unified heavy metal limits for seaweed products should be put in place throughout
Europe.
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Table 1.2: Origin and species of edible seaweed which have been listed as not novel
in EU Food Catalogue

Species Name
Ascophyllum nodosum

Origin of species
European

Eisenia bicyclis

SE Asian

Fucus vesiculosus

European

Hizikia fusiforme

SE Asian

Laminaria digitate

European

Laminaria longicruris

European

Palmaria palmata

European

Porphyra tenera

SE Asian

Saccharina japonica

SE Asian

Saccharina latissima

European

Undaria pinnatifida

European & SE Asian

Table 1.3: Maximum allowable heavy metal limits in France & tolerable weekly
intake of heavy metals in Europe.

Heavy Metals

French Maximum Heavy
Metal Limits* (mg/kg dry
weight)

Inorganic Arsenic (As)

3

European Tolerable
Weekly Intake of Heavy
Metals** (mg/kg dry
weight)
0.3-8

Cadmium (Cd)

0.5

7

Mercury (Hg)

0.1

1.6

Lead (Pb)

5

25

Tin (Sn)

5

50-200

Iodine (I)

2000

100-150

*

French heavy metal limits obtained from CEVA
European tolerable weekly intake of heavy metals obtained from ‘’Commission (EC) No 1881/2006 setting maximum levels for certain contaminants in foodstuffs’’, ‘’Commission Regulation (EC) No
2015/1006’’ and SCF (Scientific Committee for Food, 1993).

Values expressed as µg/kg bodyweight
**
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Table 1.4: Vitamin & mineral composition of selected seaweeds compared to
European recommended daily intake.
Seaweed1

Vitamin
Palmaria
palmata

Ascophyllum
nodosum

Saccharina
latissima

Ulva sp

Recommended
intakes2

A

7.44

N/D3

99*

0.2

700-600**

E

3.4

14

0.6

1.95*

K
D

0.42
0.9

1.017
1

N/D
1

N/D
1.31

0.4mg x g dietary
PUFA
65-80**
5**

C

83.6

94.8

11.3

54.6

45

B1

0.4

0.3

0.4

0.1

1-1.2

B2

0.5

1

0.3

0.3

1-1.3

B3

4.3

2.7

N/D

8.6

9-18

B9*

92

22.7

N/D

53

250-300**

B12*

9.8

2.1

N/D

9.6

0.6-1.4**

Minerals

Seaweed
Palmaria
palmata

Ascophyllum
nodosum

Saccharina
latissima

Ulva sp

Recommended
intakes

Sodium,

1659

2859

3590

1974

5000

Magnesium,

241

836

790

2776

150-500

Phosphorus,
Potassium

280
6812

162
2269

230
6180

181
1952

550
3100-3500

Calcium

547

1652

680

1198

1200-1300

Manganese

12.1

2.5

0.3

3.9

1-10

Iron

34.8

21.8

7.1

78.9

15-20

Copper

1.1

0.7

0.3

1.3

1.1

Zinc

4.2

6.4

2.5

3.7

7-9

Iodine

32.5

68.2

366

9.2

100-150**

Selenium*

9

6.7

N/D

14.9

55**

1

Mean values of vitamin & mineral composition obtained from CEVA (Centre d'Etude et de Valorisation
des Algues). Values expressed as mg/100g dry weight.
2
Mean RI values obtained EFSA (European Food Safety Authority, 2006), SCF (Scientific Committee
for Food, 1993) & World Health Organisation (WHO). Average RI’s for adults expressed as mg/day.
3
N/D = no data available
*
Values expressed as µg/100g dry weight.
**
RI’s expressed as µg/day
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6. Seaweed bioactives & gastrointestinal health
The gastrointestinal tract is a major contributor towards health as it facilitates the
absorption of many essential nutrients and acts as a barrier to the external environment.
The GI tract is one of the biggest components of the immune system as it contains
effective detection systems for the presence of antigens and a large pool of immune
cells available to mount the necessary response. However, disorders in these biological
functions can lead to development of serious gastrointestinal disorders. A survey carried
out on behalf of United European Gastroenterology determined an increase in the
prevalence of gastrointestinal disorders such as inflammatory bowel disease (IBD),
Celiac’s disease and alcoholic liver disease, as well as colorectal and pancreatic cancers
(Farthing et al., 2014). As such, effective preventative or amelioratory strategies must
be developed in order lower the burden of future healthcare. A variety of marine
bioactives have been found to exhibit anti-inflammatory, anti-tumour and anti-allergic
properties, which may prove useful in the treatment of these gastrointestinal disorders
(Islam et al., 2013; Kim et al., 2010; Sanjeewa et al., 2016). As the GI tract is the
primary interface between the diet and essential biological processes, the incorporation
of marine bioactives in functional food or pharmaceuticals may have a role in treating
and preventing these disorders.

6.1 Anti-inflammatory activities
Inflammation is a complex biological response to harmful stimuli such as pathogens and
cell injury. It utilises immune cells, blood vessels and biological mediators as a means
of removing these harmful stimuli. However, chronic inflammation is detrimental to
cells and can often lead to the pathogenesis of inflammation-derived diseases such as
gastrointestinal cancers, atherosclerosis and inflammatory bowel disease (IBD)
(Macarthur et al., 2004; Libby et al., 2002). IBD is a blanket term used to describe
chronic inflammatory conditions which affects all or part of the gastrointestinal tract.
IBD typically describes two conditions: Crohn’s disease, which affects the entire GI
tract, and ulcerative colitis, which only affects the colon. Although the exact aetiology
and pathogenesis of IBD is unknown, a combination of genetic susceptibility and
environmental factors has been linked to the initiation and progression of this
inflammatory disorder (Figure 1.7).
IBD is a global disease, with highest incidence rates being reported in industrialized
regions such as Canada and Northern Europe (Molodecky et al., 2012). Previously low
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incidence regions, such as Asia, have also experienced a dramatic increase in incidence
of IBD, which has been associated with rapid urbanization and therefore exposure to
associated environmental factors such as decreased physical activity and a more
‘’Westernized’’ diet (Yang et al., 2016). Younger populations in urbanized societies are
also becoming more affected by IBD. A study in northern France found that between
the years 1988-2007, incidence of Crohn’s disease increased by 71% in a group aged
10-19 years (Chouraki et al., 2011). Due to the increasing incidences of IBD worldwide,
an economic burden will be placed on the healthcare system as patients diagnosed with
IBD for less than 5 years have been found to have more frequent emergency room
visits, hospitalizations and hospitalizations, followed by surgery than the general
population (Longobardi et al., 2004).
Seaweed and seaweed extracts, particularly those from brown seaweed, have potent
anti-inflammatory and immunomodulatory properties, which could be utilised in the
treatment of inflammatory disorders such as IBD. These anti-inflammatory properties
have largely been tested within in vitro or animal models. Several in vitro studies have
determined the inhibitory effect of the marine carotenoid fucoxanthin on inflammatory
mediators and pro-inflammatory cytokines using lipopolysaccharide stimulated RAW
264.7 macrophages. These studies determined that fucoxanthin inhibited nitric oxide
and prostaglandin E2 production through the downregulation of inducible nitric oxide
synthase (iNOS) and cyclooxygenase 2 (COX-2) protein and mRNA expression
(Shiratori et al., 2005; Heo et al., 2010; Heo et al., 2012). Fucoxanthin has also been
found to have an inhibitory effect on the release of pro-inflammatory cytokines such as
tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (Heo
et al., 2012). Much of these anti-inflammatory activities are attributable to
fucoxanthin’s ability to reduce nuclear factor-κB (NF-κB) activity and prevent mitogenactivated protein kinase (MAPK) phosphorylation (K. N. Kim et al., 2010). A number
of other macroalgae-derived bioactives have also shown potent anti-inflammatory
activities similar to fucoxanthin in different in vitro studies including polysaccharides
such as fucoidan, algal lipids, and polyphenols such as phlorotannins as well as other
aqueous extracts (Park et al., 2011; Robertson et al., 2015; Wijesinghe et al., 2013;
Khan et al., 2008).
The potential advantages of seaweed and seaweed extracts as a nutraceutical in the
treatment and management of inflammatory GI disorders has largely been exhibited by
animal models. Two different orally administered preparations of fucoidan from the
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brown macroalgae F. vesiculosus were found to ameliorate symptoms of colitis in
murine models through the retention of body weight, reduction of diarrhoea and the
decreased production of several pro-inflammatory cytokines by colonic tissue (Lean et
al., 2015). Similar observations were found in dextran sodium sulphate (DSS)
challenged porcine models after oral administration of algal polysaccharides laminarin
and fucoidan (O’Shea et al., 2016). As there are little to no in-depth human trials,
further research in humans is necessary to fully explore the anti-inflammatory activities
of macroalgae compounds and their potential in the treatment of IBD.
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Figure 1.7: Pathogenesis of IBD. Genetic and environmental factors induce impaired
barrier function which allows translocation of microbial products into the bowel wall.
Detection of microbial products induces immune cell activation and release of proinflammatory cytokines thereby causing acute inflammation. If regulatory mechanisms
fail to resolve mucosal inflammation, chronic intestinal inflammation occurs. Chronic
inflammation can lead to tissue destruction and induction of gastrointestinal disease.
(Adapted from Neurath, 2014)
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6.2 Anti-obesity/weight management
Obesity is one of the world’s most visible yet neglected health concerns. It can be
defined as an abnormal or excessive accumulation of fat, which can present a risk to
health. According to WHO, 13% of the global population are obese, with 11% of men
and 15% of women found to be obese in 2014 (WHO, 2016). However, global obesity
rates are on the rise and, according to a recent study published in the Lancet, by 2025,
global obesity prevalence will reach 18% for men and surpass 21% for women (Ng et
al., 2014; Di Cesare et al., 2016). This presents a serious global health challenge, as
obesity is often associated with increased risk of developing other disorders, including
Type 2 diabetes, hypertension, metabolic syndrome, osteoarthritis and even some forms
of cancer. Management of body weight is one of the methods used in obesity
treatments. This is usually achieved through a permanent change in diet, food intake and
level of physical activity. In some extreme cases, anti-obesity drugs may be prescribed.
These pharmaceuticals treat obesity through a reduction in energy absorption or by
reducing fat mass, either through an increase in energy expenditure or by redistributing
adipose tissue. Currently, there are only a few anti-obesity drugs on the commercial
market, with many more undergoing clinical and pre-clinical trials. As such, there is an
increasing demand for more anti-obesity compounds, particularly from natural sources.
Potential therapeutic benefits of seaweed consumption have been reported in the
management of obesity. A recent study evaluated the effect of seaweed powder obtained
from Sargassum polycystum on rats fed with a high fat diet. Supressed weight gain was
evident in all groups and positive reductions in plasma levels of cholesterol and
triglycerides were observed in the high dosage group (Awang et al., 2013). This may be
due to the high fibre content in the seaweed species, as high fibre diets have been found
to promote weight management through delayed gastric emptying and improved postmeal satiety. Seaweed is a rich source of dietary fibres. One such example would be
alginate, a soluble dietary fibre which can be found in the cell wall of brown seaweed
and is often used in the food industry as an emulsifiers and stabilizers. Alginates have
also been added to drink formulations as a means of enhancing post-meal suppression of
hunger, although the reduction in hunger response depends on the gastric gelling ability
of the alginate used (Peters et al., 2011). As such, several studies have investigated the
potential benefits of alginates extracted from brown seaweed in weight management.
Jensen et al., (2012) investigated the effect of alginate supplementation on the weight
loss of obese subjects on an energy restricted diet for 12 weeks. A greater degree of
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weight loss were observed in those given the alginate supplement, when compared to
the placebo group, which suggests that alginate supplementation may improve weight
loss in subjects undergoing dietary intervention treatments.
Phlorotannins, fucoidan and fucoxanthin have all been identified as potential antiobesity agents. Phlorotannins have been shown to hinder adipocyte differentiation, a
strategy which could be used in the prevention and treatment of obesity. Obesity is
associated with increased proportions of adipose tissue, which can be regulated through
the suppression of adipogenesis. Phlorotannins fractions isolated from the brown
macroalgae Ecklonia stolonifera have been found to diminish expression of adipocyte
gene markers such as proliferator activated receptor γ (PPARγ) and CCAAT/enhancerbinding protein α (C/EBPα) (Jung et al., 2014). These adipokines play vital roles in the
development of fat cells and PPARγ, in particular is highly expressed in adipose tissue.
Fucoidan, fucoxanthin and fucoxanthin’s metabolite fucoxanthinaol were likewise
found to supress adipocyte differentiation, through the downregulation of PPARγ, with
fucoxanthinol exhibiting stronger suppressive effects than fucoxanthin (K. J. Kim et al.,
2010; Maeda et al., 2006).
One of the main causes for the increasing interest in brown seaweed and its derivatives
as anti-obesity agents is due to their inhibitory role against pancreatic lipase. The
inhibition of lipases, specifically pancreatic lipase, is a major target for most antiobesity drugs as the digestion and absorption of dietary lipids by pancreatic lipase
causes an excess of calorie intake. Orlistat, a commercially available anti-obesity drug,
is a potent inhibitor of gastric and pancreatic lipases. This compound inactivates the
lipases by forming covalent bonds with the active sites of the lipases. However, adverse
side effects such as diarrhoea, abdominal cramping and deficiencies in fat-soluble
vitamins limit its value to patients (Lunagariya et al., 2014). Therefore, anti-lipase
compounds from natural sources with little to no adverse side-effects are required.
Preparation from three different brown seaweeds, A. nodosum, F. vesiculosus, and
Pelvetia canaliculata were tested for anti-lipase activity. The preparations tested, which
included whole seaweed homogenate, sodium carbonate extracts and ethanol extracts,
all demonstrated significant lipase inhibition (Chater et al., 2016). This implies
numerous biologically active agents present in the seaweed, which could be utilised for
anti-obesity treatments. These bioactive agents may include alginates, polyphenols and
fucoxanthin, which have all been marked for anti-pancreatic lipase activity in previous
studies (Houghton et al., 2015; Buchholz & Melzig, 2015; Matsumoto et al., 2010).
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6.3 Anti-diabetic
Non-insulin dependent diabetes or Type II diabetes is a chronic metabolic disorder
which is characterized by increased insulin resistance, high blood glucose levels and
reduced production of insulin. There are several risk factors which can contribute to the
development of type II diabetes including genetic predisposition, lifestyle factors such
as smoking and physical activity and deficiencies in essential vitamins such as vitamin
D (Wu et al., 2014). However, type II diabetes and its precursor of insulin resistance is
usually a consequence of prolonged obesity. During obesity, increased release of factors
such as hormones, non-esterified fatty acids and pro-inflammatory cytokines contributes
to the development of insulin resistance. This insulin resistance, paired with aberrations
in pancreatic beta-cell function, results in an inability to control blood glucose levels,
thereby contributing to development of type II diabetes (Kahn et al., 2006). Type II
diabetes is a visible global epidemic. In 2013, approximately 382 million people were
estimated to have diabetes, with that number expected to rise to 592 million in 2035
(Guariguata et al., 2014). Therefore effective strategies to improve insulin sensitivity
and prevent development of type II diabetes are required.
Promising anti-diabetic effects have been identified from consumption and
supplementation with seaweed. A national survey carried out in Korea found that
dietary consumption of seaweed is associated with reduced risk of type II diabetes in
Korean men, a statement which has been illustrated in various animal and clinical
studies (Lee et al., 2010). Selvaraj & Palanisamy, (2014) observed potent
hypoglycaemic effects in alloxan-induced diabetic rats after consumption of brown
macroalgae Sargassum longiotom extracts. When compared with untreated diabetic rats,
rats administered these extracts exhibited a significant reduction in blood glucose levels.
The influence of seaweed on glycaemic control was exhibited in a clinical study
involving patients with type 2 diabetes. Patients were supplemented with tablets
composed of equal parts sea tangle (Laminaria japonica) and sea mustard (Wakame),
three times a day for approximately 4 weeks. Fasting blood glucose levels and
postprandial blood glucose levels were reduced significantly in the seaweed
supplementation group. This reduction has been linked to increased fibre content, as
those ingesting seaweed had a 2.5 higher fibre intake (Kim et al., 2008). As seaweed is
a rich source of fibre, which has been linked with improved glycaemic control in
diabetic patients, the inclusion of seaweed supplement in the diet of diabetic patients
may contribute to improved blood glucose levels.
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Several specific seaweed extracts have been associated with potent anti-diabetic
activities. Phenolic rich compounds isolated from brown seaweed in particular, have
been examined in several studies against a variety of anti-diabetic targets. These targets
include enzymes involved in glucose homeostasis, such as α-amylase and α-glucosidase,
uptake of glucose by cells through various mechanisms and release of incretin
hormones (Sharifuddin et al., 2015; Lopes et al., 2016). Dietary starch is a major source
of glucose in the diet and increase in post-prandial blood glucose concentrations are
typically caused by the hydrolysis of carbohydrates by α-amylase and α-glucosidase.
These are significant enzymes in the breakdown and absorption of carbohydrates and
inhibition of α-amylase and α-glucosidase are key targets in many anti-diabetic
treatments. Lordan et al., (2013) compared 15 native Irish seaweed species for αamylase and α-glucosidase inhibitory activities. Of those assessed, 5 seaweed species
including Ascophyllum nodosum, Fucus serratus, Fucus spiralis, Fucus vesiculosus and
Pelvetia canaliculata, were found to be strong inhibitors of α-amylase and αglucosidase activity in levels well below cytotoxicity levels. A. nodosum and F.
vesiculosus in particular, were found to be potent inhibitors of α-amylase and αglucosidase, respectively, with much of these inhibitory activities associated with
phenolic content and antioxidant activities of the seaweed species. Inhibitory activities
of A. nodosum and F. vesiculosus extracts against α-amylase and α-glucosidase have
been expressed in several other studies. Kim et al., (2014) found that fucoidan isolated
from A. nodosum inhibited both α-amylase and α-glucosidase, while fucoidan from F.
vesiculosus only inhibited α-glucosidase, which indicates their potential for diabetes
management.
Several in vitro studies have illustrated the ability of brown seaweed extracts to promote
incretin hormone secretion and thereby improve insulin secretion. A study of selected
Malaysian seaweeds found that crude water extracts of three brown seaweeds, Padina
sulcata, Sargassum binderi and Turbinaria conoides, stimulated glucose-dependent
insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion in an
endocrine cell line and inhibited the production of dipeptidyl-peptidase-4 (DPP-4) (Chin
et al., 2015). GIP and GLP-1 are gut-derived incretin hormones which promote the
secretion of insulin in a glucose-dependant manner. These incretin hormones are rapidly
hydrolysed by the enzyme DPP-4, which circulates in the body. Therefore, secretion of
incretin hormones and DPP-4 inhibition are key anti-diabetic targets. Some seaweed
extracts have been found to possess a similar efficacy to well-known anti-diabetic drugs
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in promoting insulin secretion. A study compared the ability of water, ethanol and
acetone extracts of the brown seaweed Sargassum hemiphyllum to stimulate insulin
secretion with that of the known anti-diabetic drug glibenclamide. The authors found
that all extracts stimulated insulin secretion, with the acetone extracts exhibiting similar
efficacy to glibenclamide, which was linked to the high content of polyphenol and
fucoxanthin content in the acetone extracts (Hwang et al., 2015). During a co-treatment
of extracts and glibenclamide, it was found that insulin secretion was increased to a
higher degree than with glibenclamide alone, with little to no increase in adverse side
effects. This indicates the suitability of seaweed extracts as not only an anti-diabetic
drugs but as a compound which could enhance the function of already available antidiabetic drugs.

6.4 Anti-tumour
Cancers are a group of diseases characterized by uncontrolled division of abnormal cells
in the body. Colorectal cancer is the third most common cancer worldwide, with more
than 300,000 new cases reported in Europe in 2012 (Ferlay et al., 2015) (Figure 1.8).
Although colorectal cancer death rates have decreased by 50% from peak rates, due to
improvements in early detection methods and treatment, colorectal cancer has a high
mortality rate linked to its tendency to metastasize (Siegel et al., 2016) (Figure 1.9).
Due to the rising incidence of cancer, there has been increased interest in
chemotherapeutic molecules from natural sources as a means of slowing or preventing
the progression of invasive cancers (Nobili et al., 2009). Seaweed has several
compounds which could prove useful in the treatment of colorectal cancer. (Hoshiyama
et al., 1993) found that seaweed consumption is inversely related to the risk of
developing colon and rectal cancers, through a dose-dependent relationship. A recent
animal study investigated the effect of sea mustard (Laminaria japonica) and sea tangle
(Undaria pinnatifida) consumption on the initiation of colon and liver carcinogenesis in
mouse models. The study determined that consumption of extracts from these seaweed
species may prevent the development of colon and liver cancer by inhibiting DNA
damage related to the initiation of cancer (Bu et al., 2014). As such, an abundance of in
vitro and in vivo studies have been carried out to elucidate the anti-cancer properties of
various seaweed species.
A variety of bioactive compounds, including fucoxanthin and fucoidan have been
attributed to the anti-cancer properties in seaweed. These compounds utilise several
therapeutic targets in the suppression of cancer. For example, induction of apoptosis is a
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popular target in many anti-cancer treatments. Apoptosis is a form of programmed cell
death and defective expression of apoptosis has been reported as a causative factor in
development of cancer. Fucoxanthin from the brown seaweed Undaria pinnatifia was
found to reduce cell viability in several colon cancer cell lines, as well as induce DNA
fragmentation, which is an indicator of apoptosis (Hosokawa et al., 2004). Fucoxanthin
was also found to supress expression of Bcl-2, a protein with inhibitory influence on
apoptosis. The inhibitory effect of fucoxanthin on the proliferation of colon cancer cells
can be linked to its ability to induce cell cycle arrest at the G0/G1 phase, through the
up-regulation of the cell cycle regulator p21 (Das et al., 2005). Fucoxanthin has the
potential to prevent the development of colorectal cancer initiated by prior conditions,
such as IBD and ulcerative colitis. Both of these conditions have been associated with
increased risk of developing colorectal cancer. An analysis of population based cohort
studies determined that those with ulcerative colitis had an increased risk of developing
colorectal cancer (Jess et al., 2012). Z. Kong et al., (2016) found that not only did
fucoxanthin reduce the inflammatory response of mouse models with DSS-induced
colitis, but also decreased the incidence of colonic neoplasm and increased the rate of
survival in colon associated colorectal cancer (CACC) mice.
Similar to fucoxanthin, studies have elucidated the capability of fucoidan to reduce cell
viability through the induction of apoptosis in several colon cancer cell lines (Hyun et
al., 2009; E. J. Kim et al., 2010). Other anti-carcinogenic properties of fucoidan include
the prevention of the invasion, metastasis and angiogenesis of cancer cells through the
inhibition of growth signal mechanisms. Metastasis, the development of secondary
malignant growth at a different location from the original site of cancer, is one on the
leading causes of cancer deaths and as such is a significant target in cancer treatments.
Using a hepatocarcinoma cell line, fucoidan isolated from Undaria pinnafidia
sporophylls were found to inhibit tumour metastasis in vitro in a concentration and
time-dependant manner and prevent the growth, invasion and adhesion abilities of the
cell line in vivo (Wang et al., 2014). These inhibitory actions were mediated by the
down-regulation of PI3K/Akt and ERK signalling pathways, which are often altered
during cancer thereby promoting metastasis.
The anti-angiogenic properties of fucoidan have also been expressed in the literature.
Angiogenesis is the formation of new blood vessels, which is vital for wound healing
and embryonic development. During cancer, unregulated angiogenesis can contribute to
tumour progression. A fucoidan fraction isolated from Sargassum fusiforme dose

~ 38 ~

dependently inhibited migration and tube formation of human microvascular endothelial
cells, which indicates its suitability as a potent anti-angiogenic mediator. However,
molecular weight and sulphate content of the fucoidan fraction is an important factor in
its anti-angiogenic efficacy. For example, a study compared the anti-tumour and antiangiogenic properties of over-sulphated fucoidan to normal fucoidan. It was determined
that suppressive effect of over-sulphated fucoidan on the angiogenic growth factor,
vascular endothelial growth factor 165 (VEGF165) was greater than in normal fucoidan
fractions (Koyanagi et al., 2003). This indicates that the addition of sulphate groups to
fucoidan fractions may improve the efficacy of fucoidan as an anti-cancer agent.
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Figure 1.8: Estimated incidence of cancers worldwide in 2012. Lung cancer
demonstrated highest incidence in 2012, followed by breast cancer and colorectum
cancer

Figure 1.9: Progression of colorectal cancer from normal epithelium and the main
genes involved
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7. Conclusion
The utilization of marine resources such as seaweed as a source of bioactive compounds
is still a relatively novel concept outside Asia. In many European countries the seaweed
industry itself is just starting out. With the rising global population and with it, rising
demands for food and resources, it is clear that the exploitation of untapped marine
sources is the way forward. Seaweeds, in particular brown seaweed, are compelling
sources of nutrients and novel bioactive compounds which has implications for many
chronic non-communicable diseases of the gastrointestinal tract, such as inflammatory
bowel disorder (IBD), colorectal cancer, type II diabetes and obesity. An abundance of
in vitro and in vivo trials provide the majority of data on the health benefits of these
marine bioactives and in order to further the development of marine bioactives into
functional nutraceuticals and even pharmaceuticals, reliable human data must be
achieved through clinical trials.
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Abstract
Due to rapid global urbanization and therefore increased adoption of a ‘’Westernized’’
lifestyle, including decreased physical activity and increased consumption of highly
processed and refined foods with a high sugar, fat and salt content, prevalence of
gastrointestinal disorders are on the rise. Inflammatory bowel disease (IBD) in
particular is closely associated with this type of lifestyle. IBD is a term used to describe
chronic inflammatory conditions which affects all or parts of the gastrointestinal tract. It
includes conditions such as Crohn’s disease, which affects all the gastrointestinal tract
and ulcerative colitis which mainly affects the colon. Due to the role of chronic
inflammation in the development of gastrointestinal malignancies, development of these
disorders has also been linked to increased risk of colorectal cancer.
While the exact aetiology of IBD remains unclear, key features of this disease have
been identified as therapeutic targets, such as abnormal immune responses. As such
current therapeutic methods are aimed at the suppression of these immune responses.
Along with the mentioned environmental factors, dysregulation of the gut microbiota
has been linked to the pathogenesis of IBD. The gastrointestinal tract host a complex
community of microorganisms which are integral to host’s health. Microbial dysbiosis
is a common symptom associated with IBD and is thought to contribute to the chronic
inflammatory responses observed in this disorder. However, use of immune suppressing
agents to treat IBD may increase susceptibility to foodborne or hospital infections.
With incidences of IBD increasing, novel bioactives from natural sources have been
considered as a means to manage this disorder. Seaweed and seaweed extracts,
particularly those from brown seaweed, have potent anti-inflammatory and antimicrobial properties which could be utilised in the treatment of IBD. Seaweed has also
been noted as a potential source of prebiotics, which could promote a balanced
microbial community in the gut. The aim of this project was to assess the antiinflammatory properties of extracts from four brown seaweed species Saccharina
latissima, Alaria esculenta, Ascophyllum nodosum and Fucus vesiculosus using an invitro model of gastrointestinal inflammation
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Aims of Thesis
-

To assess the anti-inflammatory properties of extracts from four brown
seaweeds : Saccharina latissima, Alaria esculenta, Ascophyllum nodosum and
Fucus vesiculosus by determining potential inhibitory activities against IL-8
production

-

To further assess the anti-inflammatory of the seaweed extracts using an in-vitro
model of gastrointestinal inflammation

-

To determine the anti-microbial properties of Saccharina latissima, Alaria
esculenta and Ascophyllum nodosum extracts against a number of bacteria
including Staphylococcus aureus, Enterococcus faecalis, Escherichia coli and
Salmonella enterica.

-

To determine whether antimicrobial properties of the seaweed extracts are
bactericidal or bacteriostatic

-

To investigate potential detrimental effects of seaweed extracts on growth
kinetics of probiotic strain Lactobacillus johnsonii.
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Chapter 2
Determination of anti-inflammatory properties of
brown seaweed extracts using in vitro models of
gastrointestinal inflammation

~ 44 ~

1. Introduction
Inflammatory bowel disease (IBD) is a term used to describe chronic inflammatory
conditions which affects all or parts of the gastrointestinal tract, for example Crohn’s
disease and ulcerative colitis. IBD is a global disease, with the highest incidences
reported in industrialized areas such as Canada and Northern Europe (Molodecky et al.,
2012). Development of these disorders has been linked to increased risk of colorectal
cancer, as chronic inflammation can cause the development of gastrointestinal
malignancies. With incidences of gastrointestinal disorders increasing across Europe, as
well as increased prevalence of IBD in previously low incidence areas, an economic
burden will be placed on the global healthcare system prompting the need for novel
therapeutics for the management of this condition.
While the exact aetiology of IBD remains unclear, understanding of the
pathophysiology of IBD has advanced, with many features of the disease acting as key
therapeutic targets. For example, compromised intestinal barrier function has been
identified as a key feature of IBD. In normal physiology the intestinal barrier is a
complex system formed by intestinal epithelial cells which has roles in the production
and regulation of mucus, controlling antigen passage by acting as a physical barrier and
interacting with the cells of the intestinal immune system. During IBD, barrier function
is disrupted causing increased permeability, reduced numbers of secretory cells,
impaired tight junctions, loss of epithelium due to the formation of ulcers and increased
passage of bacterial and dietary antigens, thereby causing increased activation of
mucosal immune cells. It has been suggested that impaired barrier function in IBD is a
consequence of increased mucosal inflammation, another common therapeutic target in
the treatment of this disorder.
Abnormal immune responses to intestinal microbes and ingested substances are a
common feature of IBD. During normal inflammatory conditions, once inflammatory
stimuli are eliminated, pro-inflammatory responses typically shift to anti-inflammatory
responses thereby downregulating the inflammation process. However, due to defects in
the function of intestinal immune cells, shifts from pro-inflammatory to antiinflammatory responses are impaired in IBD, leading to chronic inflammation in the
gastrointestinal tract. Many of these inflammatory responses are mediated by proinflammatory cytokines and chemokines such as IL-6, TNF-α, MCP-1 and IL-8 (Figure
2.1). Interleukin 8 is a chemotactic cytokine which plays a role in the pathophysiology
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of many diseases through the promotion of leukocyte migration to areas of
inflammation and the initiation of cell activation events. Several studies have found
that IL-8, along with other cytokine such as IL-6 and TNF-α, is highly expressed in
patients with inflammatory bowel disease and other forms of colitis (McCormack et al.,
2001; Mitsuyama et al., 1994). As such suppression of pro-inflammatory cytokine
release has been identified as a therapeutic target for the treatment of these
inflammatory disorders.
Current treatment methods include the use of non-biological therapies such as steroids
and aminosalicylates. However, while the therapeutics provides relief from symptoms
of IBD progression of the disease is unchanged. In the case of severe IBD, this can lead
to surgery. The introduction of anti-TNF agents such as infliximab has reduced the need
for surgeries and improved quality of life for patients by changing the progression of the
disease (Hanauer et al., 2002). However, not all patients respond to treatments and these
agents are associated with adverse side effects, including risks of infections and
development of extra-intestinal malignancies (Ford & Peyrin-Biroulet, 2013; Axelrad et
al., 2016). As a result, there has been increasing interest in alternative methods, such as
the use of nutraceuticals and bioactive dietary components, to treat IBD (Larussa et al.,
2017; Zhang et al., 2015).
Seaweed and seaweed extracts, particularly those from brown seaweed, have been
highlighted due to their rich bioactive potential. Extracts from brown seaweed has been
found to possess many bioactive properties, including anti-oxidant, anti-thrombotic,
anti-obesity, and anti-diabetic properties (O'Sullivan et al., 2011; Zhao et al., 2012;
Wan-Loy & Siew-Moi, 2016; Chin et al., 2015). Brown seaweed extracts have also
been found to possess potent anti-inflammatory and immunomodulatory properties
which could be utilised in the treatment of gastrointestinal inflammatory disorders. For
example in-vitro testing has shown that seaweed extracts reduce nitric oxide and
prostaglandin E2 production, supress the expression of pro-inflammatory genes, reduce
pro-inflammatory cytokine levels such as IL-1β, IL-6 and TNF-α and promote antiinflammatory cytokines IL-10 and IFN-y. Intake of brown seaweed extracts fucoidan,
laminarin and fucoxanthin has also been found to reduce inflammatory pathology in
animal models with induced colitis (Lean et al., 2015; O’Shea et al., 2016; Kong et al.,
2016). The objective of this study was to determine the anti-inflammatory properties of
extracts from three different species of brown seaweed; Saccharina latissima,
Ascophyllum nodosum Alaria esculenta and Fucus vesiculosus using an in-vitro model
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of gastrointestinal inflammation. The potential inhibitory effect of these extracts on IL-8
production was investigated.

Figure 2.1: Cytokines in the pathogenesis of IBD. During IBD, barrier function is disrupted,
causing increased permeability and increased passage of bacterial and dietary antigens. Presence
of these antigens promote the release of pro-inflammatory cytokines by immune cells. Adapted from
Neurath et al., (2014).
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2. Material & Methods
2.1 Seaweed materials
Extracts from brown macroalgae species Saccharina latissima, Ascophyllum nodosum,
Alaria esculenta and Fucus vesiculosus were provided by SeaRefinery partners
Cybercolloids and Marinox (Table 2.1). The brown macroalgae were harvested from
different locations (Ireland, Denmark and Scotland)(Table 2.1). Saccharina latissima
and Alaria esculunta extracts were isolated by means of water extraction (Table 2.1).
Ascophyllum nodosum extracts from different locations and different seasons were
isolated by means of methanol, ethanol or water extraction (Table 2.1). Dried extracts
were dissolved in phosphate buffer saline solution (PBS).

2.2 Cell Culture
Colon epithelial cells, CaCo-2 (obtained from EATCC), were maintained in Minimum
Essential Medium Eagle (MEM), supplemented with 10% heat inactivated foetal bovine
serum (FBS), 1% non-essential amino acids (NEAA), 2mM L-glutamine and 2mM
penicillin/streptomycin. Murine macrophage cells, J774.2 (obtained from EATCC) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10%
FBS, 2mM L-glutamine and 2mM penicillin/streptomycin. All cells were incubated at
37°C in a 5% CO2, 95% air and humidified atmosphere, in a SANYO CO2 incubator
(Model number: MCO-15AC). Frozen cell stocks were maintained at -80°C, in
complete medium and 20% dimethyl sulfoxide (DMSO). CaCo-2 cells used were in
passages numbers 43-48 and J774.2 cells were used in passages numbers 7-30.
2.2.1 Cell Sub-culture

Both CaCo-2 cells and J774.2 cells are adherent cells. Medium was changed every 2-3
days until 70-80% confluence was achieved. Once confluent, cells were sub-cultured.
To form a single cell suspension prior to sub-culturing, cells were washed with PBS and
incubated with 0.25% Trypsin, 0.2% EDTA solution at 37°C for 2-3 minutes or until
cells had detached from the flask. Trypsin activity was deactivated by the addition of
equal volumes of complete medium. Cell suspension was pelleted by centrifugation at
1,000 rpm for 4 minutes. The cell pellet was re-suspended in fresh medium and cell
numbers were enumerated. Cell suspension was either seeded at appropriate densities
for experiment or seeded in new cell culture flasks. Viable cell counts were obtained
using Trypan Blue and a haemocytometer.
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2.3 Cytotoxicity Testing
Cytotoxicity of seaweed extracts on CaCo-2 and J774.2 cell lines were investigated
using the Neutral Red uptake assay as described by Repetto et al., 2008. Cells were
seeded at 15x104 cells per well in 96 well plates and allowed to adhere overnight. Cells
were then treated with serial dilutions of seaweed extracts (200mg/ml – 1.5625mg/ml)
for 24 hours. Extracts were decanted and cells were incubated at 37°C for 2 hours in the
presence of neutral red working medium (neutral red dye diluted 1:100 in serum free
DMEM). Neutral red medium was removed, cells were washed with PBS and neutral
red de-stain solution (50% ethanol 96%, 49% deionized water & 1% glacial acetic acid)
was added. Optical density of extracted dye was read at 540nm using a
spectrophotometer. Experiments were carried out in triplicate.

2.4 Anti-inflammatory Screening
CaCo-2 cells were seeded at 1x106 cells per well in 6 well plates or 2x105 cells per well
in 24 well plates and allowed to grow to confluence. Once confluent, cells were treated
with serum free media (negative control), 1ug/ml lipopolysaccharide (LPS) (positive
control) or dilutions of seaweed extracts (200mg/ml – 3.125mg/ml) plus 1ug/ml LPS for
24 hours. Extracts used for anti-inflammatory testing were chosen based on cytotoxicity
results, origin of species, harvesting time and, in the case of Ascophyllum extracts,
polyphenol content. Cell supernatants were collected and stored at -20°C for further
analysis using ELISA’s. Treated cells were stored at -80°C for use in RNA extraction
and RT-PCR. Experiments were carried out in triplicate

2.5 Co-culture Set-up
An in-vitro model of gastrointestinal inflammation was set up as per Tanoue et al., 2008
with minor adjustments (Figure 2.2). CaCo-2 cells were seeded at 2x105 cells per well
onto 6 well Transwell inserts or 2x104 cells per well onto 12 well Transwell inserts. The
culture medium was changed every 2-3 days. Transwells were assessed visually until
cells were fully differentiated. J774.2 cells were seeded at 8x105 cells per well in 6 well
plates. Transwells containing CaCo-2 cells were then transferred into the multi-well
plates, preloaded with J774.2 cells (Figure 2.2). CaCo-2 cells were treated with
dilutions of seaweed extracts for 24 hours and J774.2 cells were stimulated with 1ug/ml
LPS for 24 hours. Supernatants from apical and basolateral sides were collected for
further analysis. Cultured cells were harvested and stored at -80°C in RNAlater for
RNA extraction and RT-PCR.
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2.6 Interleukin-8 ELISAs
Interleukin-8 Duoset ELISA’s (R&D systems) were carried out as per manufacturer’s
instructions. Microtiter plates were coated with IL-8 capture antibody and incubated
overnight at room temperature. Block buffer was added and the plate was washed three
times with wash buffer. IL-8 standards and cell supernatants were added and plate was
incubated for 2 hours. The plate was washed three times and detection antibody was
added to each well and incubated for 2 hours. The wash step was repeated and
Streptavidin-HRP was added to the plate and incubated for 20 minutes. The plate was
washed three times and the substrate solution was added and incubated for 20 minutes.
A stop solution was added to halt the colour reaction and optical density was read at
450nm.

2.7 RNA Extraction & RT-PCR
Total RNA was extracted from CaCo-2 cells using Roche High Pure RNA Isolation kit
according to manufacturer’s protocol. RNA with an A260/A280 ratio within 1.8 -2 was
used for PCR. The reverse transcription of the RNA was performed using Roche
Transcriptor First Strand cDNA Synthesis Kit according to manufacturer’s protocol.
Quantitative PCR was carried out using Roche Lightcycler 480 Probes Master kit
according to manufacturer’s instructions. After an initial incubation at 94°C for 15 min,
qPCR was performed with 45 cycles for the housekeeper gene GAPDH and the gene of
interest, IL-8.

The PCR protocol was as follows: of denaturation (95°C, 15 s),

annealing (48°C, 30s), and extension (72°C, 20s). The oligonucleotide primers and dual
labelled probes used are listed out in Table 2.2.

2.10 Statistics
All analysis was carried out in triplicate. Results are presented as mean value plus
standard error. Statistical analysis was performed using one-way analysis of variance
(ANOVA) followed by Tukey post hoc test and Student’s T-test. (Prism 5, GraphPad
Inc., San Diego, CA, USA). A P-value < 0.05 was considered statistically significant.
Within the range of significant values the following symbol were used *, p < 0.05; **, p
< 0.01; ***, p < 0.001.
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Table 2.1: Extract information provided by SeaRefinery partners Marinox and Cyber
colloids
Extract Code

Seaweed
Species

*

Extraction

Origin

Solvent

Harvesting
Time

MX121216

S. latissima

Water

Norway

May-16

MX221216

A. esculenta

Water

Norway

May-16

MX040716

F. vesiculosus

Water

Norway

Dec-16

ETAUG1608

S. latissima

Water

Ireland

July-16

CC3702

A. nodosum

Methanol

Irish

Jan-16

CC3762

A. nodosum

Ethanol

Scottish

Mar-16

CC3764

A. nodosum

Ethanol

Irish

Apr-16

IL-8/TNF-α

+/- extracts
J774.2 cells

Figure 2.2: In-vitro model of gastrointestinal inflammation. Transwell inserts on which
CaCo2 cells have been cultured were inserted into multi-well plates containing J774.2 cells.
To simulate gastrointestinal inflammation, lipopolysaccharide (LPS) was added to the
basolateral side. Seaweed extracts were added to the apical side and IL-8 and TNF-α levels
were measured after 24hrs.

*

Extracts from Saccharina latissima, Alaria esculenta, Fucus vesiculosus and Ascophyllum
nodosum originated from different locations and were harvested at different time points. A
variety of extraction methods were also used
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Table 2.2: Forward and reverse oligonucleotide primer sequences used for qPCR.

Gene

Sequence (5’ – 3’)

GAPDH

CTGCTCACATATTCTGGA
CACTCACCATGTAGTTGA

Probe

[6FAM]ATGCCTTCTTGCCTCTTGTCTCTTA[BHQ1]

CXCL8

ACGAGGTGTCTATGTAAG
GACTGATTCAGTTCACTATC

Probe*

*

[6FAM]ACTCACTCATACAGCATCACTAAGACA[BHQ1]

Hydrolysis probes for each primer pair are shown
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3. Results
3.1 Cytotoxicity of Saccharina latissima, Ascophyllum nodosum, Alaria
esculunta & Fucus vesiculosus extracts
Potential cytotoxic effect of seaweed extracts on intestinal epithelial cell line CaCo2 and
murine macrophage cell line J774.2 were assessed using Neutral Red Uptake assay.
Extracts from Saccharina latissima, Ascophyllum nodosum and Alaria esculenta were
diluted within the range of 200-3.125mg/ml (Table 2.1). No significant cytotoxic effects
were observed in either cell line treated with Saccharina samples ETAUG1608 or
MX121216, when compared with untreated cells (Figure 2.3(a), (b)). Ascophyllum
sample CC3702 was found to significantly promote viability of CaCo2 cells at
concentrations of 100mg/ml (p<0.01), 50mg/ml and 25mg/ml (p<0.001), while the
higher concentration of 200mg/ml significantly reduced the viability of J774.2 cells
(p<0.01) (Figure 2.3(c)). Higher concentrations (200mg/ml – 25mg/ml) of CC3762 and
CC3764 also significantly increased viability of CaCo2 cells (p<0.001) (Figure 2.3 (d)(i
), Figure 2.3(e)(i)). No significant change in viability was observed in J774.2 cells
treated with CC3762 while cells treated with 200mg/ml (p>0.01), 100mg/ml and
50mg/ml (p>0.001) of CC3764 had significantly higher viability when compared with
untreated cells (Figure 2.3(d)(ii), Figure 2.3(e)(ii)).

~ 53 ~

Concentration

~ 54 ~

Concentration

5

12

3.

25

6.

.5

12

25

m

g/
m
l

m
l

g/

m

l

l

m
l

g/

m

g/
m

m

g/
m

m

m
l

5

12

3.

25

6.

.5

12

25

50

m
l

m
l
g/

m

l

l

m
l
g/

m

g/

m

g/
m

m

g/
m

m

m
l

m
l

g/

m

Concentration

50

Concentration

g/

0

m

50

0

100

m
l

**

10

***
g/

0

0

50

g/

ol

tr

100

10

on

on
tr
ol
m
10 g/m
l
0
m
g/
50 ml
m
g
25 /ml
m
12 g/m
.5
l
m
g/
6.
25 ml
m
3.
g/
12
m
l
5
m
g/
m
l

C

20
0

0

% Viability
(relative to untreated cells)

50

m

C

150

% Viability
(relative to untreated cells)

100

0

20

m
l

m
l

g/

m

l

m
l

g/

m

g/

m

l

on
tr
ol
m
g
/m
10
l
0
m
g/
50 ml
m
g
25 /ml
m
12 g/m
.5
l
m
g
6.
25 /ml
m
3.
g/
12
m
l
5
m
g/
m
l
20
0

C

150

m

l

ro

200

% Viability
(relative to untreated cells)

5

25

12

3.

6.

.5

g/
m

m

g/
m

m

m
l

m
l

g/

m

ol

tr

g/

m

on

% Viability
(relative to untreated cells)
200

0

20

g/
m
l

m
l

(c) (i)

on
t

m

g/

m

l

m
l

g/

m

12

25

50

0

10

0

20

C

% Viability
(relative to untreated cells)

(b) (i)

C

5

25

12

3.

.5

g/
m

m

l

***

6.

12

g/
m

m

m
l

g/

m

l

m
l

g/

m

ro

on
t

150

25

50

0

10

0

20

C

% Viability
(relative to untreated cells)

(a) (i)
(a) (ii)
200

150

100
50
0

Concentration

(b) (ii)
150

100

50

0

Concentration

(c) (ii)
150

100

**

50

0

(d) (ii)

l
g/
25 ml
m
12 g/m
.5
l
m
g/
6.
25 ml
m
3.
g/
12
m
l
5
m
g/
m
l

m

Concentration
(e) (ii)

***

300

***

200

***

***

100

20
0

C
on
tr
ol
m
10 g/m
l
0
m
g/
50 ml
m
g
25 /ml
m
12 g/m
.5
l
m
g
6.
25 /ml
m
3.
12 g/m
l
5
m
g/
m
l

0

Concentration

400
300

***
**

200

***

100
0

C
on
tr
ol
m
10 g/m
l
0
m
g/
50 ml
m
g
25 /ml
m
12 g/m
.5
l
m
g/
6.
25 ml
m
3.
12 g/m
l
5
m
g/
m
l

% Viability
(relative to untreated cells)

400

20
0

(e) (i)

% Viability
(relative to untreated cells)

50

20

Concentration

m

m

m

g/

tr
on
C

m

50

l

ol

0

m

l

g/

m
m
0
10

0

m

g/

tr
on
20

C

l
g/
25 ml
m
12 g/m
.5
l
m
g/
6.
25 ml
m
3.
g/
12
m
l
5
m
g/
m
l

0

50

g/

50

100

m

100

150

0

***

***

200

10

***

0

***
150

% Viability
(relative to untreated cells)

200

ol

% Viability
(relative to untreated cells)

(d) (i)

Concentration

Figure 2.3(a), (b), (c), (d), (e): Percentage viability of (i) CaCo2 cells and (ii) J774.2 cells after
overnight treatment with (a) ETAUG1608, (b) MX121216 (c) CC3702, (d) CC3762 and (e)
CC3764. Statistical analysis completed using one-way ANOVA where *, p < 0.05; **, p < 0.01;
***, p < 0.001
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3.2 Anti-inflammatory properties of seaweed extracts
In order to progress with testing seaweed extracts in an in-vitro model of
gastrointestinal inflammation, anti-inflammatory properties of extracts needed to be
evaluated. Expression of pro-inflammatory chemokine Interleukin-8 in the presence of
extracts plus bacterial lipopolysaccharide was evaluated using ELISA assays.
Saccharina sample MX121216, Alaria extract MX221216 and Fucus extract
MX040517 from Denmark demonstrated potent inhibitory activities against the
secretion of IL-8. In all three extracts, all dilutions (200mg/ml – 1.5625mg/ml)
significantly inhibited IL-8 production (p < 0.001) (Figure 2.4(a), (b), (c)). When
compared to the positive control (i.e. LPS treated cells), percentage inhibition of IL-8
production by cells treated with median concentrations of extracts (25mg/ml) were
64.4%, 73.1% and 66.1% for MX121216, MX221216 and MX040517, respectively.
Ascophyllum extract CC3764 had a similar broad inhibitory effect on IL-8 production.
CC3764 significantly inhibited IL-8 production at a concentration range of 200mg/ml –
3.125mg/ml (p < 0.001) with median concentration of 25mg/ml inhibiting IL-8
production by 86.8% when compared with the positive control (Figure 2.4(d)).
Ascophyllum extracts CC3702 and CC3762 and Saccharina extract ETAUG1608
demonstrated a narrower inhibitory range against IL-8 production. CC3702 and CC3762
inhibited Il-8 protein expression at concentrations ranging from 200mg/ml – 12.5mg/ml
(p < 0.001). While inhibitory effects of ETAUG1608 were observed at concentrations
range of 200mg/ml – 25mg/ml (Figure 2.4(e), (f), (g)). When compared to LPS treated
cells, IL-8 levels in cells treated with 25mg/ml extracts were inhibited by 90.1%, 86.9%
and 65.3% for CC3702, CC3762 and ETAUG1608, respectively.
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Figure 2.4 (a), (b), (c), (d), (e), (f), (g) : Fold change in IL-8 protein expression after 24hr treatment with
LPS plus concentrations of (a) MX121216, (b) MX221216, (c) MX040517, (d) CC3764, (e) CC3702, (f)
CC3762 and (g) ETAUG1608. Statistical analysis completed using one-way ANOVA where *, p < 0.05;
**, p < 0.01; ***, p < 0.001

3.3 In-vitro model of gastrointestinal inflammation
Once the anti-inflammatory activities of the extracts were demonstrated and a viable
concentration chosen (25mg/ml), extracts were tested in an in-vitro model of
gastrointestinal inflammation (Figure 2.2). This concentration was chosen as it was the
lower concentrations (12.5mg/ml -3.125mg/ml) demonstrated decreased inhibitory
activities against IL-8 production. This model, composed of human intestinal epithelial
cells and murine immune cells, is used to simulate gastrointestinal inflammation as it
occurs in the host. All extracts at 25mg/ml significantly reduced IL-8 levels in the invitro model (p<0.001) (Figure 2.5(a)). Ascophyllum extracts CC3702, CC3762 and
CC3764 demonstrated similar levels inhibition of IL-8 (88.2%, 87.8% and 88.5%,
respectively) while in cells treated with Alaria extract MX221216 and Fucus extract
MX040517 had 80.5% and 59.5% inhibition, respectively, of IL-8 respectively when
compared with the positive control. In contrast to the Ascophyllum samples, the two
Saccharina samples ETAUG1608 and MX121216 displayed differing levels of IL-8
inhibition. ETAUG1608 inhibited IL-8 release by 67.3%, while MX121216
demonstrated a 79.1% inhibition of IL-8. Potential inhibitory activities of chosen
seaweed extracts against mRNA expression of IL-8 were also investigated. All extracts
displayed significant suppressive effects against IL-8 mRNA expression (Figure 2.5(b))
(p<0.05). Saccharina extracts ETAUG1608, Fucus extract MX040517 and Alaria
extract MX221216 (p<0.001) had more significant inhibitory activities against IL-8
mRNA expression when compared with the other extracts. Between the Ascophyllum
extracts, CC3764 had a more significant inhibitory action (p<0.01) against IL-8 mRNA
expression, when compared with CC3702 and CC3762 (p<0.05).
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Figure 2.5 (a), (b): Fold change in IL-8 protein levels and mRNA expression after 24hr treatment
with seaweed extracts in an in-vitro model of gastrointestinal inflammation. Statistical analysis
completed using one-way ANOVA where *, p < 0.05; **, p < 0.01; ***, p < 0.001

Table 2.3: Fold change in IL-8 protein and mRNA expression after treatment with
seaweed extracts.

Fold change in IL- Fold change in ILExtract

Seaweed species

8 mRNA

8 protein

expression*

expression

+ Control

N/A

16.63

2.68

MX121216

S. latissima

0.05

0.52

MX221216

A. esculunta

5.27

0.49

MX040517

F. vesiculosus

2.18

0.93

ETAUG1608

S. latissima

5.94

0.77

CC3702

A. nodosum

4.48

0.30

CC3762

A. nodosum

2.97

0.30

CC3764

A. nodosum

1.94

0.28

*

Results calculated based off negative control. All values expressed as average of triplicate
experiments
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4. Discussion
Inflammatory bowel disease (IBD) is a chronic inflammatory condition which affects
the gastrointestinal tract and is often linked with increased risk of developing colorectal
cancer, due to the role of chronic inflammation in the development of gastrointestinal
malignancies. Current therapeutic methods to manage IBD include the use of nonbiological agents and Anti-TNF agents, which manage symptoms of the disorder and
can induce remission through the suppression of the immune system. However, while
these treatments are generally regarded as safe, not all patients respond to these methods
and side effects such as nausea, abdominal pain, development of opportunistic
infections and development of malignancies are a concern (Rogler, 2010; Stallmach et
al., 2010). As a result, research has turned to natural bioactives with minimal side
effects as a means to manage IBD. Seaweed extracts have recently become of interest
due to their potent bioactive properties, including immunomodulatory and antiinflammatory activities, which could be utilised in the management of inflammatory
conditions. The main objective of the present study was to investigate the antiinflammatory properties of extracts from four species of brown seaweed i.e. Saccharina
latissima, Ascophyllum nodosum, Alaria esculenta and Fucus vesiculosus. Brown
macroalgae used in the study were harvested from different locations, at different timepoints and extracts were isolated using water, methanol and ethanol extraction methods.
In order to determine suitability of extracts, potential cytotoxic effects were first
investigated. While the Saccharina extracts ETAUG1608 and MX121216 demonstrated
no cytotoxic effects, higher concentrations of A. nodosum extracts CC3702, CC3762
and CC3764 promoted the proliferation of the intestinal epithelial cell line, CaCo-2 as
viability of treatment cells had a higher percentage viability when compared with
control cells. Jiang et al. (2010) observed a similar growth promoting effect in the
canine kidney cell line, MDCK when treated with concentrations of ascophyllan (Jiang
et al., 2010). Ascophyllan is a sulphated polysaccharide which is distinguishable from
fucoidan by its bioactivities and by the presence of a backbone of uronic acid with
fucose-containing branches (3-O-D-xylosyl-l-fucose-4-sulfate). As fucoidan from the
same A. nodosum proved cytotoxic to MDCK cells and ascophyllan has not been found
in Saccharina species, it implies that the proliferative effect of the crude A. nodosum
extracts observed in this study may be attributed to their ascophyllan content (Jiang et
al., 2010). One of the main features which characterize IBD is severe damage to the
epithelial layer by the inflammatory environment. Though current immunomodulatory
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therapies for IBD, including anti-TNF agents, demonstrate good control of
inflammatory responses, regeneration of the epithelial layer is regarded as poor
(Okamoto, 2011). It has been suggested that long term remission of IBD is linked to
‘mucosal healing’, which can be defined as the complete repair of the epithelial layer at
both endoscopic and microscopic level (Pineton de Chambrun et al., 2016). As such,
mucosal healing is a therapeutic target for the management of IBD. Current treatments
used for IBD have been found to be capable of promoting mucosal healing, though
effectiveness is difficult to assess due to different study designs, different definitions of
mucosal healing and different timing of endoscopic examinations (Papi et al., 2013).
Therefore, when investigating natural alternatives treatments of IBD, bioactives with
both anti-inflammatory properties and ability to induce mucosal healing are ideal. The
proliferative effect of Ascophyllum extracts observed in this study could be utilised in
the promotion of mucosal healing in IBD, though further study is required.
Abnormal inflammatory responses such as the over-production of pro-inflammatory
cytokines are a common feature in the pathophysiology of IBD. Bioactives isolated
from seaweed such as fucoxanthin, fucoidan, polyphenols and algal lipids have been
shown to have potent immunomodulatory and anti-inflammatory activities against a
number of inflammatory mediators and pro-inflammatory cytokines which could be
utilised in the treatment of IBD (Kim et al., 2010; Heo et al., 2012; Park et al., 2011;
Wijesekara et al., 2011; Robertson et al., 2015). In order to assess suitability of brown
seaweed extracts in the treatment of IBD, this study investigated potential antiinflammatory properties of the extracts against interleukin-8 production. Interleukin-8
(IL-8) is a chemotactic cytokine which is produced in high concentration in patients
with IBD and other forms of colitis (McCormack et al., 2001). Induction of IL-8 in the
intestinal epithelium triggers recruitment of neutrophils to the lamia propria, though
activation, mucosal injury and trans-epithelial migration requires additional activation
signals (Kucharzik et al., 2005). All extracts tested in this study significantly inhibited
IL-8 levels in CaCo-2 cells stimulated with lipopolysaccharide (LPS), an inflammatory
bacterial component. However, four extracts were found to have a wider range of
inhibitory activities against IL-8 levels when compared with the other extracts. The
lowest inhibitory concentration observed in S. latissima samples were 25mg/ml, for the
Irish S. latissima sample ETAUG1608, and 1.5625mg/ml, for the Norwegian S.
latissima samples MX121216. As all S. latissima samples were extracted using a water
extraction method and a similarly wide inhibitory range was observed in the Norwegian
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A. esculenta and F. vesiculosus extracts, this implies that origin of the source seaweed
has an impact on the bioactivity of the extracts. Seaweed origin also had an impact on
A. nodosum extract efficacy as Scottish A. nodosum CC3762 had a narrower inhibition
range than Irish A. nodosum CC3764, with the lowest inhibitory concentration identified
as 12.5mg/ml while the lowest inhibitory concentration of CC3764 was identified as
3.125mg/ml. However, the origin of source seaweed may not be the only factor
impacting bioactivity of extracts. For example, harvesting season has been identified in
several studies as a source of variation which is due to the changes in water temperature,
light intensity, salinity and presence of essential nutrients caused by the changing
seasons. Dar et al., (2007) found that extracts from the tropical seaweed Sargassum
wightii harvested in spring (February – April) and summer months (May – July)
displayed weaker anti-inflammatory properties when compared to those harvested in
winter months (November – January). This differs from results obtained in this study
for the A. nodosum, as extract harvested in winter and spring months (CC3702 and
CC3762 respectively) has a narrower inhibitory range against IL-8 release when
compared with the extract harvested in summer (CC3764). Therefore, in order to
optimize bioactive efficacy, optimum harvesting season for each seaweed species
should be determined.
The anti-inflammatory activities of these brown seaweed extracts were further
demonstrated using an in-vitro model of gastrointestinal inflammation, as established by
Tanoue et al., (2008). The in-vitro model, comprised of human intestinal epithelial cells
and murine immune cells, was established as a means to determine anti-inflammatory
activities of food factors at the cellular level. Murine immune cells are stimulated with
bacterial lipopolysaccharide, which then affects the layer of epithelial cells, thereby
simulating the abnormal immune responses observed in IBD and other forms of colitis.
All seaweed extracts tested at the chosen concentration of 25mg/ml significantly
reduced IL-8 protein levels in this in-vitro model. This concentration was chosen as it
was the lowest effective inhibitory concentration. Lower concentrations demonstrated
decreased inhibitory activities against IL-8 production. However, the A. nodosum and
A. esculenta extracts demonstrated a higher IL-8 inhibition (>80%) when compared
with the F. vesiculosus extract (59.5%) indicating that this species of seaweed may have
weaker anti-inflammatory properties. The Norwegian S.latissima demonstrated a higher
degree of IL-8 inhibition (79.1%) when compared with the Irish S.latissima (59.5%),
which could be attributed to differences in seaweed origin and seasonal change. The
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anti-inflammatory properties of these extracts could be attributed to their suppressive
effects on IL-8 mRNA expression. Similar suppressive effect of seaweed extracts on
protein levels and mRNA expression of pro-inflammatory cytokines has been observed
in other studies (Wijesinghe et al., 2013; Park et al., 2011).
It is clear that extracts from brown seaweed species, particularly from Saccharina
latissima, Alaria esculenta, and Ascophyllum nodosum, have potent anti-inflammatory
properties which could be utilised in the treatment of gastrointestinal inflammatory
disorders. The anti-inflammatory properties of these extract have been observed in
normal physiological conditions, indicating that the use of these seaweed extracts as
anti-inflammatory agents should only be prescribed to those in diseased states
(Appendix I). However, influence of seasonal change and origin of harvested material
should be considered as barriers to the year round formulation of consistent bioactives.
Further assessment of the these extracts could include determining potential inhibitory
effects on additional pro-inflammatory chemokines and cytokines, including MCP-1,
CCL20, IL-6 and IL-1β, and assessing potential suppressive effect on inflammatory
mediators such as nitric oxide production, prostaglandin E2 (PGE2) production and
nuclear factor-kappa (NF-κB) activation. Extracts should also be further assessed using
animal models and human trials in order to determine whether these extracts have
similar effects in-vivo as in-vitro.
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Chapter 3
Anti-microbial properties of brown seaweed
extracts
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1. Introduction
Seaweeds are classified as Rhodophyta (red macroalgae), Chlorophyta (green
macroalgae) or Phaeophyta (brown macroalgae) depending on their pigmentation,
structure and biochemical composition. These marine plants survive and live in
complex environments and are often exposed to varying environmental conditions. In
response to these conditions, marine macroalgae (particularly those in fixed positions)
produce a number of secondary metabolites which may aid in survival. A number of
these metabolites limit the growth of competitive microorganisms and prevents the
settlement of fouling organisms (Zerrifi et al. 2018). Algal extracts and their purified
components have also been found to exhibit anti-oxidant, anti-cancer, anti-inflammatory
and anti-coagulant activities which are of interest to the food and pharmaceutical
industry (O'Sullivan et al. 2011; Kim et al. 2010; Robertson et al. 2015; Cumashi et al.
2007).
Brown seaweed extracts have been reported to be active against a number of Gram
negative and Gram positive bacteria, with a greater efficacy than extracts from red and
green seaweed (Gupta et al., 2010; Gupta et al., 2012; Cox., 2010). This may be due to
a selection of bioactive compounds found in brown seaweed which are not be found in
red or green seaweed including fucoidan, a sulphated polysaccharide mainly found in
the cell wall of brown macroalgae, phlorotannin, a tannin only found in brown
macroalgae, and fucoxanthin, a pigment which gives brown macroalgae its colour.
These bioactives have shown inhibitory activities against a number of microorganisms
(Liu et al., 2017; Vijayabaskar et al., 2012; Eom et al., 2012; Rajauria & AbuGhannam, 2013). Some studies have attributed antimicrobial activity with phenolic
content of brown seaweed extracts, as phenolic compounds have several modes of
actions which could inhibit bacterial growth, such as damaging the microorganism’s
cell walls and cell membranes resulting in the release of intracellular components
(Gupta & Abu-Ghannam, 2011).
An area in which the anti-bacterial properties of seaweed extracts could be utilised is in
the maintenance of gastrointestinal health. The gastrointestinal tract hosts a complex
community of symbiotic micro-organisms, which interacts with the digestive tract, to
promote gut homeostasis. This gut microbiota consists of approximately 100 trillion
micro-organisms, including bacteria, fungi and viruses, in varying concentrations, along
the GI tract. The gut microbiota plays a vital role in maintaining host health as it is
involved in the development of healthy immune responses, acts as a natural defensive
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barrier against infection and is involved in metabolic processes such as the anaerobic
fermentation of carbohydrates and the proteolytic fermentation of metabolites such as
phenolic compounds, amines and ammonia. As the gut microbiota is intrinsic to host
health, imbalances in the microbial community caused by environmental changes such
as diet and lifestyle have been linked to the pathology of certain gastrointestinal
disorders such as obesity, colorectal cancer and inflammatory bowel disorder (IBD). For
example, microbial dysbiosis is a common symptom associated with IBD and is thought
to contribute to the chronic inflammatory responses observed in this disorder. Common
treatments of IBD also involve the use of immune supressing agents, which may
promote susceptibility to hospital or foodborne infections.
The aim of this chapter was to determine potential anti-microbial properties of extracts
from three brown seaweed species : Saccharina latissima, Alaria esculenta and
Ascophyllum nodosum against a number of bacteria relevant to gastrointestinal health
(Staphylococcus aureus, Enterococcus faecalis, Escherichia coli and Salmonella
enterica). These bacterial species were selected due to their potential role in the
pathogenesis of IBD or due to their potential role as causative agents of infection in
immunocompromised patients with IBD. A probiotic strain, Lactobacillus johnsonii,
was also tested with these extracts in order to investigate potential activity against
normal flora of the host and to determine if there are any prebiotic activities of these
extracts.
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2. Materials and Methods
2.1 Seaweed Materials
Extracts from brown macroalgae species Saccharina latissima, Ascophyllum nodosum
and Alaria esculenta were provided by SeaRefinery partners Cybercolloids and
Marinox (Table 3.1). The brown macroalgae were harvested from different locations
(Ireland, Denmark and Scotland) (Table 3.1). Saccharina latissima and Alaria esculunta
extracts were isolated by means of water extraction with differing protocols (Table 3.1).
Ascophyllum nodosum extracts from different locations and different seasons were
isolated by means of methanol, water or sodium hydroxide and ascorbic acid extraction
(Table 3.1). Dried extracts were dissolved in phosphate buffer saline solution (PBS).

2.2 Microbial culture
Five species of bacteria were selected based on their relevance to gastrointestinal health,
the food industry and clinical background. The bacteria selected were Staphylococcus
aureus, Enterococcus faecalis, Lactobacillus johnsonii, Escherichia coli and Salmonella
enterica subsp. typhimurium. All cultures were maintained at -80°C in 40% glycerol
and grown in Tryptic Soy Broth (TSB) at 37°C except for Lactobacillus johnsonii
which was grown in De Mann, Rogosa and Sharpe (MRS) broth at 37°C.

2.3 Growth curves in the presences of seaweed extracts
The influence of different concentrations of seaweed extracts on the growth kinetics of
the seven organisms was assessed using 96 well microtiter plates. Overnight cultures of
bacteria were diluted to 0.5 McFarland standards in sterile Ringers. Suspension was
then diluted 1:100 in sterile broth to achieve a final cell concentration of 1x106 CFU/ml.
To assess the anti-bacterial activity of seaweed, 200ul of highest concentration of
seaweed extract (200mg/ml) was added to the second row of each plate. The other wells
were filled with 100ul broth and 100ul from the first well was serial diluted 2-fold along
each column. Equal volumes of bacterial suspension were added to each well. The first
row of each plate was used for bacterium and media controls. Samples blanks for each
concentration of the extracts were also prepared. Plates were incubated for 24 hours in a
plate reader at 37°C. Turbidity was measured as absorbance at 600nm with 5s agitation
before each OD measurement.
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2.4 Bacteriostatic assay
Extract concentrations with anti-microbial properties were then determined to be
bacteriostatic or bactericidal. Anti-bacterial assays were carried out as described
previously in ‘’2.3. Growth curves in the presences of seaweed extracts’’. After a 24
hour incubation, control bacteria and anti-bacterial dilutions plus bacteria were
transferred to 1ml sterile Ringer’s solution in Eppendorf tubes. The tubes were then
centrifuged at 1,500rpm for 5 minutes or until a pellet was formed. The pellet was
washed twice with sterile Ringer’s, re-suspended and diluted to a 0.5 McFarland
standards in sterile Ringers. Suspensions were then diluted 1:100 in sterile TSB to
achieve a final cell concentration of 1x106 CFU/ml. The microtiter plates were filled
with 100ul sterile TSB broth. Equal volumes of bacterial suspension were added to
triplicate wells. Plates were incubated for 24 hours in a plate reader at 37°C. Turbidity
was measured as absorbance at 600nm with 5s agitation before each OD measurement.
Extracts were determined to be bacteriostatic if bacteria resumed growth in fresh media.

2.5 Statistics
All analysis was carried out in triplicate. Results are presented as mean plus standard
error. Statistical analysis was performed using two-way analysis of variance (ANOVA)
followed by Bonferroni post hoc test (Prism 5, GraphPad Inc., San Diego, CA, USA). A
P-value < 0.05 was considered statistically significant. Within the range of significant
values the following symbol were used *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Table 3.1: Extract information provided by SeaRefinery partners Marinox and
Cybercolloids.

Extract Code

Seaweed Species*

Extraction

Origin

Solvent

Harvesting
Time

MX121216

S. latissima

Water

Norway

May-16

MX221216

A. esculenta

Water

Norway

May-16

ETAUG1608

S. latissima

Water

Ireland

July-16

CC3689

A. nodosum

Sodium hydroxide

Ireland

Jan-16

& ascorbic acid

*

Extracts from Saccharina latissima, Alaria esculenta and Ascophyllum nodosum originated
from different locations and were harvested at different timepoints. A variety of extraction
methods were used.
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3. Results
3.1 Anti-bacterial & bacteriostatic properties of Norwegian Saccharina
latissima
In order to determine the anti-bacterial properties of selected seaweed extracts, growth
kinetics of Staphylococcus aureus, Enterococcus faecalis, Escherichia coli and
Salmonella enterica were observed in the presence of concentrations of seaweed
extracts. Extracts from Norwegian Saccharina latissima demonstrated growth inhibitory
activities on all bacteria, but to differing degrees. When compared to the control
(bacteria in media), after 24 hours, significant growth inhibition of S. aureus was
observed at 200mg/ml, 100mg/ml, 50mg/ml, 25mg/ml (P>0.001) and 12.5mg/ml
(P<0.01) (Figure 3.1(a)(i)). Percentage inhibition estimated for these concentrations
were 94.25% for 200mg/ml, 100% for 100mg/ml, 50mg/ml and 25mg/ml and 29.23%
for 12.5mg/ml (Table 3.2). Similar inhibitory activities were observed for E. faecalis at
concentrations of 200mg/ml – 12.5mg/ml (P<0.001) (Figure 3.1(b)(i)) with percentage
inhibition ranging from 82 – 100%. Minimum inhibitory concentration (MIC) of
S.latissima extracts were determined to be 12.5mg/ml, for S. aureus and E. faecalis. In
the case of E. coli and S. enterica, the S.latissima extract significantly inhibited growth
at all concentrations with MIC identified as 6.25mg/ml (P<0.001) (Figure 3.1(c)(i),
(d)(i)). Percentage inhibition of the highest concentration of the extract (200mg/ml) was
determined to be 100% for both E. coli and S. enterica, with the inhibition rate
decreasing with lower concentrations (Table 3.2). In order to determine whether antimicrobial activity of the Saccharina extract was bactericidal or bacteriostatic, bacteria
were removed from extracts and re-grown in fresh media. As all bacteria resumed
growth after removal of extract concentrations, Norwegian S. latissima extract was
determined to be bacteriostatic. (Figure 3.1(a)(ii), (b)(ii) (c)(ii), d(ii)).
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Table 3.2: Percentage inhibition of S. aureus, E. faecalis, E. coli and S. enterica in
the presence of Norwegian Saccharina latissima

Concentration

S. aureus

E. faecalis

E. coli

S. enterica

200

94.25

86.61

100

100

100

100

100

100

51.83

50

100

100

97.17

59.84

25

100

100

63.05

36.77

12.5

29.23

82.05

49.98

30.42

6.25

N/A

N/A

37.66

28.71

(mg/ml)
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(a)(i)

(a)(ii)
0.5

Absorbance @ 600nm

0.4
0.3
0.2
0.1
0.0

Control
200mg/ml
100mg/ml
50mg/ml
25mg/ml
12.5mg/ml
6.25mg/ml

0.4
0.3
0.2
0.1

Time(h)

22
24

0.5

Absorbance @ 600nm

0.4
0.3
0.2
0.1

Control
200mg/ml
100mg/ml
50mg/ml
25mg/ml
12.5mg/ml
6.25mg/ml

0.4
0.3
0.2
0.1

24

20
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18

12
14

8
10

6

0

24
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16
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8
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6

4

2

0

4

0.0

0.0

2

Time(h)

Time(h)

(c)(i)

(c)(ii)
0.4
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0.3
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0.3
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0.1
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14

12

8
10

6

4

2
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12
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10

6
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0.0

Control
200mg/ml
100mg/ml
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12.5mg/ml
6.25mg/ml

Time(h)

(d)(i)

(d)(ii)
0.6
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0.6
0.5
0.4
0.3
0.2
0.1
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0.3
0.2
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Time(h)
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6

4
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0.0
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25mg/ml
12.5mg/ml
6.25mg/ml

0.5

8
10

Absorbance @ 600nm

18
20

(b)(ii)

0.5

Absorbance @ 600nm

14
16

Time(h)

(b)(i)

Absorbance @ 600nm

8
10
12

6

4

0

24

22

20

18

16

14

8
10
12

6

4

2

0

0.0

2

Absorbance @ 600nm

0.5

Time(h)

Figure 3.1: (i) Growth kinetics and (ii) recovery of selected bacteria (a) Staphylococcus
aureus, (b) Enterococcus faecalis, (c) Escherichia coli, (d) Salmonella enterica in the presence
of Norwegian Saccharina latissima. Significant growth inhibition against all bacteria was
observed at 200mg/ml – 12.5mg/ml when compared to control.
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3.2 Anti-bacterial & bacteriostatic properties of Irish Saccharina latissima
Significant growth inhibition of all bacteria was observed when grown in the presence
of 200mg/ml and 100mg/ml of Irish S.latissima extract (P<0.001) (Figure 3.2(a)(i),
(b)(i), (c)(i), (d)(i)). The extract demonstrated a narrow inhibition range for the chosen
Gram + bacteria, S. aureus and E. faecalis, as MIC was determined to be 50mg/ml.
Percentage inhibition for S. aureus

and E. faecalis was estimated at 100% for

200mg/ml (Table 3.3). A wider inhibitory range was observed for the chosen Gram –
bacteria, with MIC determined to be 6.25mg/ml for E. coli and S. enterica (Table 3.3).
Significant growth inhibitory effects were observed at 200mg/ml – 25mg/ml for these
bacteria (P<0.001). Percentage inhibition for E. coli was estimated at 100% for
200mg/ml and 88.46% for 100mg/ml. Dose dependant inhibition was observed for S.
enterica with 100% for 200mg/ml with inhibition rate decreasing with lower
concentrations (Table 3.3). As observed for the Norwegian Saccharina extract growth
of bacteria resumed after removal of extract, indicating bacteriostatic activity rather than
bactericidal (Figure 3.2(a)(ii), (b)(ii), (c)(ii), (d)(ii)).
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Table 3.3: Percentage inhibition of S. aureus, E. faecalis, E. coli and S. enterica in the
presence of Irish Saccharina latissima

Concentration

S. aureus

E. faecalis

E. coli

S. enterica

200

100

100

100

100

100

51.61

61.24

88.46

69.99

50

0.25

6.64

29.70

73.7

25

N/A

N/A

40.64

43.0

12.5

N/A

N/A

36.60

N/A

6.25

N/A

N/A

39.92

N/A

(mg/ml)
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(a)(i)

(a)(ii)
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24
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Figure 3.2: (i) Growth kinetics and (ii) recovery of selected bacteria (a) Staphylococcus aureus, (b)
Enterococcus faecalis, (c) Escherichia coli, (d) Salmonella enterica in the presence of Irish
Saccharina latissima. Significant growth inhibition of S. aureus and E. faecalis were observed at
200mg/ml and 100mg/ml when compared to the control. Significant growth inhibitory activities
against E. coli and S. enterica were observed at 200mg/ml – 25mg/ml.
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3.3 Anti-bacterial & bacteriostatic properties of Alaria esculenta
Extracts from Alaria esculenta demonstrated growth inhibitory activities on selected
bacteria. Significant growth inhibition of S. aureus was observed at 200mg/ml,
100mg/ml and 50mg/ml (P<0.001) with percentage inhibition of these concentrations
determined to be 100%, 100% and 97.82%. Similar growth inhibitory activity was
observed in E. faecalis at 200mg/ml, 100mg/ml and 50mg/ml (P<0.001) (Figure
3.3(a)(i), (b)(i))(Table 3.4). MIC of the extract on tested Gram + bacteria was 25mg/ml.
In the case of E. coli, growth was significantly inhibited at 200mg/ml (P<0.001) and
50mg/ml (P>0.05) Percentage inhibition of 200mg/ml was determined to be 100%.
Growth of S. enterica was significantly inhibited at all concentrations (P<0.001) with
highest concentration inhibiting growth by 70% (Figure 3.2(c)(i), (d)(i)). All bacteria
resumed growth after removal of extracts, indicating bacteriostatic activity of Alaria
esculenta (Figure 3.3(a)(ii), (b)(ii), (c)(ii), (d)(ii))
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Table 3.4: Percentage inhibition of S.aureus, E.faecalis, E.coli and S.enterica in the
presence of Alaria esculenta
Concentration

S. aureus

E. faecalis

E. coli

S. enterica

(mg/ml)
200

100

100

100

70

100

100

100

38.02

54.83

50

97.82

84.66

51.53

46.64

25

9.29

9.67

17.73

36.46

12.5

N/A

N/A

N/A

36.54

6.25

N/A

N/A

21.89

38.37
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(a)(i)

(a)(ii)
0.3

Absorbance @ 600nm

0.2

0.1

0.0

Control
200mg/ml
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Figure 3.3: (i) Growth kinetics and (ii) recovery of selected bacteria (a) Staphylococcus aureus,
(b) Enterococcus faecalis, (c) Escherichia coli, (d) Salmonella enterica in the presence of Alaria
esculenta. Significant growth inhibition of S. aureus, E. faecalis and E. coli were observed at
200mg/ml – 50mg/ml. Growth inhibition of S. enterica was observed at all concentrations of the
extract when compared to the control

~ 78 ~

3.4 Anti-bacterial & bacteriostatic properties of Ascophyllum nodosum
Extracts from Ascophyllum nodosum significantly hindered growth of chosen Gram +
bacteria at concentrations of 200mg/ml, 100mg/ml and 50mg/ml (Figure 3.4 (a)(i),
(b)(i)). Highest percentage inhibition of 100% was observed at 200mg/ml and MIC was
determined to be 6.25mg/ml (Table 3.5). Anti-microbial effects of this extract were less
effective against chosen Gram – bacteria (Figure 3.4(c)(i), (d)(i)). Significant inhibitory
activities against E. coli were observed at 200mg/ml, 100mg/ml and 50mg/ml
(P<0.001), (P<0.01) to a lesser degree than observed on S. aureus and E. faecalis as
growth was inhibited by 71.51% at 200mg/ml. Significant reduction of S. enterica by A.
nodosum extract was only observed at the highest concentration 200mg/ml (P<0.001)
with a 76.39% reduction in growth. All other concentrations inhibited growth by
approximately 20% with MIC determined as 25mg/ml. Growth of bacteria resumed
after removal of extracts, indicating bacteriostatic activity of A. nodosum (Figure 3.4
(a)(ii), (b)(ii), (c)(ii), (d)(ii)).
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Table 3.5: Percentage inhibition of S. aureus, E. faecalis, E. coli and S. enterica in
the presence of Ascophyllum nodosum

Concentration

S. aureus

E. faecalis

E. coli

S. enterica

200

100

100

71.51

76.39

100

86.75

82.21

30.45

21.31

50

50.78

78.30

11.71

19.69

25

37.01

33.93

N/A

19.7

12.5

36.97

33.33

N/A

N/A

6.25

14.38

26

N/A

N/A

(mg/ml)
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Figure 3.4: (i) Growth kinetics and (ii) recovery of selected bacteria (a) Staphylococcus
aureus, (b) Enterococcus faecalis, (c) Escherichia coli and (d) Salmonella enterica in the
presence of Ascophyllum nodosum. Significant growth inhibition of S. aureus, E. faecalis and
E. coli were observed at 200mg/ml – 50mg/ml when compared to the control. Growth
inhibition of S. enterica was only observed at 200mg/ml.
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3.5 Growth kinetics of Lactobacillus johnsonii in the presence of Saccharina
latissima, Alaria esculenta and Ascophyllum nodosum
In order to assess potential detrimental effects of seaweed extracts on normal human gut
flora, anti-microbial activity of the extracts were assessed against probiotic strain
Lactobacillus johnsonii. Concentrations of 200mg/ml (P<0.001) and 100mg/ml
(P<0.01) of the Norwegian S. latissima (MX121216) were found to significantly reduce
the growth of L. johnsonii, with a 93.78% reduction observed at 200mg/ml (Figure
3.5(a))(Table 3.6). Similar growth inhibitory effects were observed with the A.
esculenta extract with significant growth inhibition at 200mg/ml (P<0.001), 100mg/ml
(P<0.01) and 50mg/ml (P<0.001) (Figure 3.5(b)). However, 200mg/ml of this extract
only inhibited growth by 31.38% (Table 3.6). In contrast, only the highest concentration
of the Irish S. latissima extract (200mg/ml) caused significant growth inhibition
(P<0.001). However, at 50mg/ml (P<0.01) and 25mg/ml (P<0.001) Irish extract
promoted growth of L. johnsonii when compared to the control. No growth inhibition
was observed in L. johnsonii in the presence of the A. nodosum extract. Concentrations
of 100mg/ml, 50mg/ml and 25mg/ml promoted the growth of L. johnsonii when
compared to the control, indicating potential prebiotic effects of A. nodosum. Bacterial
growth resumed after removal of extracts indicating bacteriostatic activity of seaweed
extracts (data not shown) (Appendix II).
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Table 3.6: Percentage inhibition of Lactobacillus johnsonii in the presence of
seaweed extracts*

Concentration

MX121216

MX221216 ETAUG1608

CC3689

(mg/ml)
200

93.78

31.38

100

N/A

100

32.72

26.62

N/A

N/A

50

N/A

42.21

N/A

N/A

25

N/A

17.93

N/A

N/A

*

Norwegian Saccharina latissima (MX121216), Alaria esculenta (MX221216), Irish
Saccharina latissima (ETAUG1608) and Ascophyllum nodosum (CC3689)
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Figure 3.5: Growth kinetics of Lactobacillus johnsonii in the presence of (a) Norwegian
Saccharina latissima (MX121216) (b) Alaria esculenta (MX221216) (c) Irish Saccharina
latissima (ETAUG1608) and (d) Ascophyllum nodosum (CC3689). Growth of L. johnsonii was
inhibited in the presence of Norwegian S. latissima and A. esculenta. Growth of L. johnsonii
was promoted in the presence of 100-25mg/ml of the Irish S. latissima and A. nodosum
extracts.
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4. Discussion
Marine plants such as seaweeds live in complex communities and are often exposed to a
number of environmental conditions throughout the year. Seaweeds grow in close
proximity to other marine organisms and have the ability to survive with a competitive
and hostile environment. Although these plants are sessile and have no physical
defences, they produce a series of complex secondary metabolites in response to these
ecological pressures in order to ensure survival of the seaweed. These bioactives have
been linked to a number of properties which are of interest to the food and
pharmaceutical industry such as anti-oxidant, anti-inflammatory, anti-cancer, antilipidemic and anti-diabetic (Yin Chia et al., 2015; Heo et al., 2012; Kim et al., 2010;
Jung et al., 2014; Selvaraj & Palanisamy, 2014). Seaweeds have also been identified as
novel sources of anti-microbial compounds (Pérez et al., 2016). In general, seaweeds
have a symbiotic relationship with the microbial community in its natural environment,
as cultivation in axenic conditions have been linked to stunted growth and abnormal
morphology (Singh et al., 2011). However, these marine plants have been seen to
produce a number of anti-microbial compounds to prevent the growth and settlement of
competitive and fouling organisms (Zerrifi et al., 2018). Several studies have illustrated
the anti-microbial properties of seaweed extracts against a number of Gram + and Gram
– bacteria which could be utilised by the food and pharmaceutical industry. Brown
seaweed extracts in particular have been found to have a greater efficacy when
compared with red and green seaweed extracts (Cox, 2010; Gupta et al., 2012).
An area in which the anti-microbial properties of seaweed extracts could be of use is in
the maintenance of gastrointestinal health. The gastrointestinal tract contains a complex
community of microorganisms, called the gut microbiota, which plays a critical role in
host health and defence. Imbalances in the gut microbiota caused by environmental
conditions such as diet or by enteric infections have negative impacts on host health. In
fact, the pathophysiology of several gastrointestinal disorders such as colorectal cancer
and inflammatory bowel disorder (IBD) has been linked to imbalances in the microbial
community. For example it has been well understood that infections can initiate onset
and relapse of IBD (Irving & Gibson, 2008). Due to the nature of the disease, patients
are often predisposed to infections and the use of immune suppressors as treatment
methods for IBD may cause increased susceptibility to opportunistic pathogens. Patients
with IBD, particularly those with ulcerative colitis, were found to have a higher
incidence of Clostridium difficile associated diarrhoea (CDAD) when compared with
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non-IBD patients, with the majority of infections acquired before hospitalization
(Rodemann et al., 2007). The purpose of this study is to investigate the anti-microbial
properties of extracts from three brown seaweed species, Saccharina latissima, Alaria
esculenta and Ascophyllum nodosum, on a selection of bacteria relevant to
gastrointestinal health. The chosen seaweed extracts were tested against two Gram +
(Staphylococcus aureus and Enterococcus faecalis) and two Gram – bacteria
(Escherichia coli and Salmonella enterica).
Staphylococcus aureus is a major opportunistic human pathogen which causes a variety
of disease in clinical and community settings. Despite a wide variety of antimicrobial
agents available, several strains of this species display resistance to antibiotics causing
infection to spread. While S. aureus has not been identified as a causative agent of IBD,
resistant strains such as methicillin resistant Staphylococcus aureus (MRSA) is a major
concern for immune-compromised patients in clinical settings. Hospitalized patients
with IBD are at increased risk of MRSA when compared with patients with non-IBD
gastrointestinal issues and general medical inpatients (Nguyen et al., 2010). The
introduction of natural anti-microbial agents either as a food component or as a natural
supplement for IBD patients may act as a preventative measure against the
establishment of such opportunistic infections. In this study all extracts tested inhibited
the growth of S. aureus to differing degrees (MX121216 < CC3689 < MX221216 <
ETAUG1608). The A. nodosum extract (CC3689) and the Norwegian S. latissima
extract (MX121216) had a wider inhibition range when compared with the other
extracts indicating their suitability as an anti-microbial agent against S. aureus. When
compared with the Norwegian S. latissima (MX121216), the Irish S. latissima only
inhibited S. aureus growth at two concentrations (200mg/ml & 100mg/ml). As both
extracts were extracted using water as a solvent and source material were harvested in
the same season, origin of the source seaweed material may be a contributing factor to
the differences in anti-microbial activity.
Similar inhibitory results on the growth of E. faecalis were observed with A. nodosum
and Norwegian S. latissima demonstrating more of an inhibitory effect when compared
with A. esculenta and Irish S. latissima. Increased abundance of the Enterobacteriaceae
has been associated with inflammatory gastrointestinal disorders such as IBD (Lupp et
al., 2007). Increased levels of Enterococcus faecalis, a common intestinal microbe, have
been associated with clinically active Crohn’s disease (Zhou et al., 2016). It has also
been suggested through the use of animal models, that E. faecalis may play a causative
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role in the development of IBD in genetically susceptible hosts (Balish & Warner,
2002). Due to the bacteriostatic activity of these extracts, the use of A. nodosum, S.
latissima and A. esculenta extracts as anti-microbial agents may be a novel method for
maintaining the growth levels of this potentially detrimental bacterium in diseased
states. Smith et al., (2011) found that dietary supplementation with laminarin from
Laminarin digitata in pigs with LPS induced colitis reduced populations of
Enterobacteriaceae and enhanced cytokine release.
Both E. coli and S. enterica play a role in gastrointestinal health. Typically strains of E.
coli can be found as natural components of the gut microbiota. However, a group of
mucosal associated E. coli strains called the adherent and invasive E. coli (AIEC) have
been isolated from newly diagnosed patients with Crohn’s disease and ulcerative colitis
which suggests that this group of bacteria may play a role in the early onset of these
disorders (Sepehri et al., 2011). While the E. coli strain used in this study was not a
member of this group, future research could utilise the inhibitory activity of the seaweed
extracts against these AIEC in order to prevent onset of these inflammatory disorders.
In the case of S. enterica, increased risk of developing IBD has been reported in
individuals post Salmonella induced gastroenteritis (Rodríguez et al., 2006). IBD
patients receiving immunomodulators are also at a greater risk of infection from this
species due to supressed immune reactions. Recommended treatment of this type of
infection would be the introduction of antibiotics and to withhold immunomodulatory
therapy until infection is resolved, although re-infection could occur (Rahier et al.,
2009). Therefore, the use of natural compounds such as seaweed bioactives with both
anti-inflammatory activities (as seen in previous study) and anti-microbial activity
against Salmonella species could be incorporated into treatments for those with IBD.
Both Norwegian and Irish S. latissima, as well as the A. esculenta, were the most
effective at inhibiting growth of E. coli and S. enterica with the A. nodosum extract
identified as least effective (MX121216 < ETAUG1608 < MX221216 < CC3689). This
may indicates that the variation between inhibitory activity of the S. latissima extracts
observed in the Gram + bacteria may be due to composition of the extracts, rather than
origin of seaweed material. As the extracts used in this study were crude extracts, the
exact composition is unclear. However, it is reasonable to assume from results obtained
from Gram + bacteria S. aureus and E. faecalis, that the Irish S. latissima contained
lower levels of effective bioactives when compared with Norwegian S. latissima.
Therefore Gram – bacteria such as E. coli and S. enterica may be more sensitive to
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bioactives from S. latissima while Gram + bacteria such as S. aureus and E.faecalis are
more sensitive to the A. nodosum extract.
Composition for seaweed bioactives are often affected by variations in the extraction
method. Due to the chemical nature of seaweed bioactives, extraction requires
optimization in each case in order to ensure maximum production of antimicrobials.
Both S. latissima samples were extracted under similar conditions using water as a
solvent. However, a potential variation between methods may be by the use of dry
material (Irish S. latissima) vs wet material (Norwegian S. latissima). Drying is an
important step in the extraction process as loss of valued antimicrobials could occur at
high temperatures. Cox et al., (2012) found that extracts from fresh Himanthalia
elongata achieved the highest inhibition against a number of foodborne pathogens when
compared with extracts from dried H. elongata. Similarly Shanmughapriya et al.,
(2008) found that the drying process removed the antimicrobial capabilities of several
species of seaweed. Therefore, in order to achieve highest antimicrobial activity, use of
fresh seaweed material is recommended.
A potential barrier towards the use of these extracts is the possible detrimental effects
against the host’s natural flora. Therefore, the antimicrobial effects of these extracts
were determined against Lactobacillus johnsonii, a probiotic strain which resides in the
intestine. The highest concentrations of Norwegian S. latissima and A. esculenta
(200mg/ml – 50mg/ml) demonstrated growth inhibitory activity against L. johnsonii. As
this range contains the most effective inhibitory concentrations against chosen
pathogenic bacteria this would indicate that in order to maintain balance of the
microbial community in the gut, treatment using these extracts would require the
addition of a probiotic. Bacteriostatic activity of extracts may also be an advantage in
this case as re-growth of affected host bacteria may restore normal composition of gut
flora. However, more in depth research in order to determine potential antimicrobial
effects on additional members of the gut microbiota are required.
The highest concentration of the Irish S. latissima also inhibited the growth of L.
johnsonii. However, lower concentrations (100-25mg/ml) of the Irish S.latissima extract
and the A. nodosum extract promoted the growth of the L. johnsonii demonstrating
prebiotic activity. These prebiotic effects may indicate a high concentration of algal
polysaccharides in the extracts. Algal polysaccharides have been marked as potential
prebiotics due to their ability to selectively promote the growth of beneficial bacteria
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while inhibiting the growth of pathogenic strains. For example, sulphated
polysaccharides from Laminarin japonica and E.prolifera fermented by faecal cultures
were found to promote growth of Lactobacillus and Bifidobacterium species (Kong et
al., 2016). The use of prebiotics has been highlighted as an emerging therapy for IBD
and other gastrointestinal inflammatory disorders (Langen & Dieleman, 2009). While
several substances have claimed to be prebiotics, so far only fructo-oligosaccharides,
inulin, galacto-oligosaccharide and lactulose have met the criteria required for
prebiotics (non-digestible, selective and fermentative ability). Therefore, further studies
are required to investigate the non-digestibility, fermentative ability and selectivity of
these extracts in order to assess their suitability as prebiotics.
The findings of the present study indicate that extracts from Saccharina latissima,
Alaria esculenta and Ascohyllum nodosum have demonstrated bacteriostatic properties
against a number of bacteria to differing degrees. These antimicrobial properties could
be utilised in the maintenance of gastrointestinal health through the prevention of
opportunistic infections and by monitoring the growth levels of detrimental bacteria
such as E. coli and E. faecalis in diseased states. A barrier towards the use of these
extracts as a natural antimicrobial supplement is their potential detrimental effects on
the composition of the gut microbiota. While prebiotic effects were observed at lower
concentrations of S. latissima and A. nodosum, further research is required to test the
antimicrobial efficacy of these extracts using in-vitro models of the gut microbiota or
through the use of animal trials.
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Conclusions
With rising global incidences of gastrointestinal disorders such as inflammatory bowel
disease (IBD), the use of novel therapeutic compounds to treat these disorders is of
interest to the pharmaceutical industry. Current treatment methods of IBD typically
include the use immune of supressing agents such as Anti-TNF compounds. However,
not all patients respond to this course of treatment and adverse side effects such as
increased susceptibility to infections and potential gastrointestinal malignancies are a
concern. Therefore, the identification of a novel anti-inflammatory compound with antimicrobial activities could be of interest to the pharmaceutical industry either as a
therapeutic or as a natural supplement. Seaweeds, in particular brown seaweed, are
compelling sources of novel bioactive compounds which has implications for many
chronic non-communicable diseases of the gastrointestinal tract, such as IBD.
The aims of this thesis were to assess both the anti-inflammatory and anti-microbial
properties of extracts from four brown seaweed species Saccharina latissima, Alaria
esculenta, Ascophyllum nodosum and Fucus vesiculosus. S. latissima, A. esculenta and
A. nodosum demonstrated potent inhibitory activities against the production of
Interleukin-8 (IL-8), which is a chemotactic cytokine highly expressed in patients with
IBD. These anti-inflammatory activities have been attributed to their suppressive effects
on IL-8 mRNA expression. However, as these extracts also reduced IL-8 production in
normal conditions, intake of these extracts should be limited to those suffering
gastrointestinal inflammation. Extracts from S. latissima, A. esculenta and A. nodosum
also demonstrated bacteriostatic activities to differing degrees against a number of
pathogenic

bacteria

including

Staphylococcus

aureus,

Enterococcus

faecalis,

Escherichia coli and Salmonella enterica, which could prevent the establishment of
opportunistic infections. However, at 25mg/ml, which is the chosen effective antiinflammatory concentration assessed in the in-vitro model, no consistent anti-microbial
activity across all extracts was determined, which implies that effective anti-microbial
concentration needed to compliment the anti-inflammatory activities is dependent on the
extract selected. Further work using animal or clinical trials is required to assess
whether anti-inflammatory and anti-microbial activities of these extracts are applicable
in vivo.
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Figure A.1: Fold change in IL-8 protein expression after 24hr treatment with 25mg/ml of Irish S.
latissima (ETAUG1608), Irish A. nodosum (CC3702, CC3762), Scottish A. nodosum (CC3764),
Norwegian S. latissima (MX121216), A. esculenta (MX221216) and F. vesiculosus (MX040517).
Statistical analysis completed using one-way ANOVA where *, p < 0.05; **, p < 0.01; ***, p <
0.001

~ 111 ~

Appendix II
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Figure A.2: Regrowth of Lactobacillus johnsonii after the removal of (a) Norwegian
Saccharina latissima (MX121216) (b) Alaria esculenta (MX221216) and (c) Irish
Saccharina latissima (ETAUG1608). Growth of L. johnsonii resumed at all concentrations
for MX221216 and ETAUG168. Growth of L. johnsonii resumed at 50mg/ml and 25mg/ml
for MX121216
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